Biocept (BIOCQ) 10-K 11 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Mar. 02, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	1044378
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding			15,966,052
Entity Public Float		$14,155,783

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$5,364,582	$69,178
Accounts receivable	10,600	9,200
Inventories, net	188,728	92,823
Prepaid expenses and other current assets	338,721	799,131
Total current assets	5,902,631	970,332
Fixed assets, net	662,422	358,887
Other non-current assets, net	23,194	500
Total assets	6,588,247	1,329,719
Current liabilities:
Accounts payable	641,406	1,540,618
Accrued liabilities	698,833	2,242,058
Line of credit		1,981,000
Notes payable, net		5,200,599
Warrant liability	1,070	2,140,532
Supplier financings	33,674	218,925
Current portion of equipment financing	55,800
Total current liabilities	1,430,783	13,323,732
Non-current portion of equipment financing, net	68,801
Credit facility, net	4,754,516
Non-current interest payable	54,537
Deferred rent	500,179	462,001
Total liabilities	6,808,816	13,785,733
Commitments and contingencies (see Note 19)
Shareholders’ (deficit):
Series A convertible preferred stock, $0.0001 par value, 100,000,000 authorized; 69,421,047 issued and outstanding at December 31, 2013; liquidation preference of $41,652,628 at December 31, 2013; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2014 (see Note 2).		6,942
Common stock, $0.0001 par value, 53,000,000 authorized; 185,550 issued and outstanding at December 31, 2013; 40,000,000 authorized; 4,449,603 issued and outstanding at December 31, 2014 (see Notes 2 and 21).	445	19
Additional paid-in capital	138,066,008	109,958,001
Accumulated deficit	-138,287,022	-122,420,976
Total shareholders’ (deficit)	-220,569	-12,456,014
Total liabilities and shareholders’ (deficit)	$6,588,247	$1,329,719

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value		$0.00
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	40,000,000	53,000,000
Common stock, shares issued	4,449,603	185,550
Common stock, shares outstanding	4,449,603	185,550
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	100,000,000
Preferred stock, shares outstanding	0	69,421,047
Preferred stock, shares issued	0	69,421,047
Preferred stock, liquidation preference		$41,652,628

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenues	$133,415	$134,245
Cost of revenues	2,170,548	2,329,900
Gross loss	-2,037,133	-2,195,655
Operating expenses
Research and development expenses	4,497,790	3,086,737
General and administrative expenses	5,201,997	2,513,136
Sales and marketing expenses	2,137,004	148,903
Loss from operations	-13,873,924	-7,944,431
Other income/(expense)
Interest expense, net	-1,789,680	-2,070,064
Change in fair value of warrant liability	-200,936	782,112
Total other income/(expense)	-1,990,616	-1,287,952
Loss before income taxes	-15,864,540	-9,232,383
Income tax expense	-1,506	-800
Net loss & comprehensive loss	($15,866,046)	($9,233,183)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	3,997,797	181,762
Diluted	3,997,797	181,762
Net loss per common share:
Basic	($3.97)	($50.80)
Diluted	($3.97)	($50.80)

Statements_of_Shareholders_Def

Statements of Shareholders' Deficit (USD $)	Total	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2012	($27,384,895)	$2,718	$16	$85,800,164	($113,187,793)
Beginning balance, shares at Dec. 31, 2012		27,175,213	160,393
Stock-based compensation expense	952,521			952,521
Stock issuance for RSU			2	-2
Stock issuance for RSU, shares	21,846		21,846
Exercise of stock options	20,105		1	20,104
Exercise of stock options, shares	4,021		4,021
Repurchase of common shares	-4,111			-4,111
Repurchase of common shares, shares			-710
Shares issued for conversion of notes payable and accrued interest	22,812,404	4,224		22,808,180
Shares issued for conversion of notes payable and accrued interest, shares		42,245,834
Reclassification of warrant liability derivative due to triggering event	381,145			381,145
Net loss	-9,233,183				-9,233,183
Ending balance at Dec. 31, 2013	-12,456,014	6,942	19	109,958,001	-122,420,976
Ending balance, shares at Dec. 31, 2013		69,421,047	185,550
Stock-based compensation expense	1,822,661			1,822,661
Shares issued for conversion of Series A Preferred Stock		-6,942	165	6,777
Shares issued for conversion of Series A Preferred Stock, shares	69,421,047	-69,421,047	1,652,851
Shares issued for conversion of notes payable and accrued interest	7,111,999		71	7,111,928
Shares issued for conversion of notes payable and accrued interest, shares			711,202
Reclassification of warrant liability derivative due to triggering event	2,475,620			2,475,620
Shares issued for initial public offering	16,458,104		190	16,457,914
Shares issued for initial public offering, shares			1,900,000
Warrants issued in connection with credit facility	233,107			233,107
Net loss	-15,866,046				-15,866,046
Ending balance at Dec. 31, 2014	($220,569)		$445	$138,066,008	($138,287,022)
Ending balance, shares at Dec. 31, 2014			4,449,603

Statements_of_Shareholders_Def1

Statements of Shareholders' Deficit (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Debt, principal amount converted	$6,600,000	$20,231,000
Accrued interest [Member]
Accrued interest on convertible debt converted	$500,000	$2,600,000

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($15,866,046)	($9,233,183)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	251,203	266,554
Inventory reserve	-13,779	-70,004
Stock-based compensation	1,822,661	952,521
Non-cash interest expense related to convertible debt, credit facility and other financing activities	1,445,068	2,066,287
Change in fair value of warrant liability	200,936	-782,112
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	-1,400	9,685
Inventory	-82,126	38,464
Prepaid expenses and other current assets	-401,355	-37,691
Other non-current assets	-28,894	268,583
Accounts payable	-981,869	-175,280
Accrued liabilities	-1,042,160	233,852
Non-current interest payable	54,537
Deferred rent	38,178	259,961
Net cash used in operating activities	-14,605,046	-6,202,363
Cash Flows From Investing Activities
Purchases of fixed assets	-394,925	-711
Net cash used in investing activities	-394,925	-711
Cash Flows From Financing Activities
Proceeds from exercise of stock options		20,105
Payments for repurchase of shares		-4,111
Principal payments on equipment financing	-23,250
Net proceeds from issuance of common stock	17,390,240
Payments on supplier and other third party financings	-192,511	-154,998
Payments on line of credit	-2,346,000
Proceeds from borrowings on line of credit	365,000	1,981,000
Proceeds from issuance of convertible notes and warrants	175,000	4,245,000
Net proceeds from borrowings on credit facility and warrants	4,926,896
Net cash provided by financing activities	20,295,375	6,086,996
Net increase/(decrease) in Cash and Cash Equivalents	5,295,404	-116,078
Cash and Cash Equivalents at Beginning of Period	69,178	185,256
Cash and Cash Equivalents at End of Period	5,364,582	69,178
Cash paid during the period for:
Interest	402,075	3,777
Taxes	$800	$800

Statements_of_Cash_Flows_Paren

Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Common stock, shares issued for restricted stock units		21,846
Common stock, par value	$0.00	$0.00
Debt, principal amount converted	$6,600,000	$20,231,000
Preferred stock, par value		$0.00
Warrant coverage amount		502,605
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings	135,222	309,000
Cost related to IPO issuance	63,111	538,318
Liability for associated unpaid invoices	63,111	328,221
Financed insurance premium through third party financing	62,774	122,777
Cancellation of insurance premiums amount, other	44,559
Cancellation of insurance premiums partial amount received	10,955
Series A Preferred Stock, shares converted to common stock	69,421,047
Common stock, shares issued upon conversion of Series A Preferred Stock	1,652,851
Overallotment issued to underwriter to purchase common stock, period	45 days
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000
Purchase of common stock by underwriters to cover overallotments, per share	$9.30
Purchase of common stock by underwriters to cover overallotments, grant date fair value	202,143
Warrants to purchase common stock, period	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value	544,116
Underwriter IPO costs	279,760
Non-cash discount	1,330,000
Conversion price of notes	$10
Additional costs incurred prior to, and associated with IPO, beginning of period	932,136
Purchases of fixed assets	19,546
Fixed assets purchased under capital lease obligations	140,267
April 2014 Credit Facility [Member]
Warrants to purchase common stock, period	10 years
Issuance of warrants to purchase shares of common stock, grant date fair value	233,107
Common Stock [Member]
Common stock, shares issued for restricted stock units		21,846
Convertible Note converted into preferred/common stock	163,399
Series A Preferred Stock, shares converted to common stock	1,652,851
Aegis Capital Corp. [Member]
Issuance of warrants to purchase shares of common stock	95,000
Exercise price of warrants	$12.50
2008 Convertible Note [Member]
Debt, principal amount converted	1,400,000
2013 Convertible Bridge Notes [Member]
Debt, principal amount converted	5,165,000
Accrued interest on convertible debt converted	313,017
Convertible Note converted into preferred/common stock	548,803
Conversion price of notes	$10
Convertible Bridge Notes And Line Of Credit [Member]
Warrants reclassified to additional paid-in capital	2,475,620
Exercise price of warrants	$10
Warrants reclassified to additional paid-in capital	387,152
Accrued interest [Member]
Accrued interest on convertible debt converted		2,581,000
Accrued interest [Member] | 2008 Convertible Note [Member]
Accrued interest on convertible debt converted	233,982
Variable Underlying Exercise [Member]
Warrants reclassified to additional paid-in capital		236,799
Fixed Underlying Exercise [Member]
Warrants reclassified to additional paid-in capital		$144,346
Series A Convertible Preferred Stock [Member]
Convertible Note converted into preferred/common stock		42,245,834

The_Company_and_Business_Activ

The Company and Business Activities	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
The Company and Business Activities
	1. The Company and Business Activities
	Biocept, Inc. (“the Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.
	The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures CEE microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic tests in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The tests the Company offers are classified as laboratory developed tests (LDTs), under the CLIA regulations.
	In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.

Initial_Public_Offering

Initial Public Offering	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Initial Public Offering	2. Initial Public Offering
	Pursuant to an underwriting agreement dated February 4, 2014 between the Company and Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein, an IPO of 1,900,000 shares of common stock at $10.00 per share was effected on February 5, 2014. The closing of the sale of these shares to the underwriters occurred on February 10, 2014. The Company received, after deducting underwriting discounts and additional costs paid to the underwriters, approximately $17.4 million of net cash proceeds from the sale of these 1,900,000 shares. The total increase in capital as a result of the sale of these shares was approximately $16.5 million after deducting $0.9 million of additional non-underwriter costs incurred that are netted against these proceeds under applicable accounting guidance. Additionally, the underwriters were granted a 45 day option from the closing date of the IPO to purchase up to 285,000 shares of common stock at $9.30 per share to cover overallotments with a grant date fair value of approximately $202,000 (see Note 5), which was not exercised. In addition, designees of Aegis were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock at $12.50 per share with a term of five years and a grant date fair value of approximately $544,000 (see Note 5).
	On February 4, 2014, as contemplated by the registration statement covering the IPO, 69,421,047 shares of outstanding Series A Preferred Stock were converted into 1,652,851 shares of common stock and the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock.
	In connection with the closing of the Company’s IPO on February 10, 2014, (i) the $1,400,000 principal amount and $233,982 of accrued interest related to the convertible note issued in 2008 were converted at $10.00 per share into a total of 163,399 shares of common stock, (ii) the $5,165,000 principal amount and $313,017 of accrued interest related to the convertible notes issued in 2013 were converted at $10.00 per share into a total of 547,794 shares of common stock, (iii) the exercise price of the warrants associated with the convertible notes issued in 2013 was fixed at $10.00 per share for an aggregate 258,249 shares of common stock, (iv) the exercise price of the warrants associated with the $2,578,104 of collateral provided to secure the Company’s line of credit was fixed at $10.00 per share for an aggregate 128,903 shares of common stock, (v) 73,151 shares of common stock vested as settlement of certain restricted stock units (which were previously expressed in shares of preferred stock) and became issuable subsequent to the expiration of the 180 day lock-up period, (vi) the Company’s Executive Chairman ceased to be an employee and continues to serve as non-executive Chairman, (vii) the number of shares of common stock covered by the Company’s 2013 Equity Incentive Plan increased by 800,000, (viii) all but 1,587 of the preferred warrants previously outstanding were canceled due to early termination clauses associated with the IPO, (ix) derivative warrant liabilities of $2,475,620 associated with the aggregate of 387,152 common stock warrants related to the convertible notes issued in 2013 and line of credit were reclassified to additional paid-in capital when their underlying exercise price was fixed, (x) unamortized discounts of $996,024 related to the warrants associated with the convertible notes issued in 2013 and line of credit were reclassified to interest expense, and (xi) offering costs associated with the IPO of $932,136 were reclassified from prepaid expenses and other current assets to additional paid-in capital, while additional underwriter IPO costs and discounts of $279,760 and $1,330,000, respectively, were netted against the proceeds from the IPO and are reflected as an offset to additional paid-in capital.
	Subsequent to December 31, 2013, the maximum amount of the Company’s line of credit was increased to approximately $2.6 million and common stock warrants were issued to four shareholders in conjunction with their guarantees on the Company’s additional borrowings under the line of credit. On February 10, 2014, the current outstanding balance under the line of credit of $2,346,000 plus accrued interest of $27,043 was paid in full using the net proceeds from the IPO.
	On February 13, 2014, the Compensation Committee of the Company’s Board of Directors approved the payment of an aggregate $1,009,552 in deferred salary obligations, including contractual interest, to current and former named executive officers pursuant to previously existing agreements, which was fully disbursed by April 2014 using the net proceeds from the IPO. An additional $344,883 in deferred salary obligations and interest thereon was paid to former employees other than named executive officers. Also on February 13, 2014, in connection with the closing of the IPO and pursuant to a resolution for a director compensation policy adopted in 2013, the Company’s Board of Directors approved annual cash retainers to non-employee directors, and granted 238,500 stock options under the Company’s 2013 Equity Incentive Plan to non-employee directors. These option awards vest in equal annual installments over 3 years from the date of grant with a 10 year term, subject to continuing service requirements. In February 2014, the Company’s Board of Directors approved grants of 54,298 stock options as a result of the closing of the IPO pursuant to the terms of underlying employment agreements. Included in the stock options granted pursuant to the terms of underlying employment agreements are 53,108 option awards granted to the Company’s non-executive Chairman, which vested fully on the date of grant.
	Under the terms of certain employment agreements with executive officers, the Company incurred additional cash compensation expense of $150,000 immediately, and $225,000 annually, upon the closing of its IPO. All payments required under these agreements as a result of the closing of the Company’s IPO on February 10, 2014 were subsequently made in February and March 2014, using the net proceeds from the IPO.
	During the year ended December 31, 2014, the Company repaid in full the remaining amounts outstanding of approximately $70,000 due for laboratory equipment under financing agreements with a supplier, which is a business owned by a member of the Company’s Board of Directors, using the net proceeds from the IPO.

Liquidity

Liquidity	12 Months Ended
	Dec. 31, 2014
Cash And Cash Equivalents [Abstract]
Liquidity	3. Liquidity
	At December 31, 2013 and December 31, 2014, the Company had accumulated deficits of approximately $122.4 million and $138.3 million, respectively. For the years ended December 31, 2013 and 2014, the Company incurred net losses of approximately $9.2 million and $15.9 million, respectively. The Company borrowed a total of $6.2 million and $0.5 million during the years ended December 31, 2013 and 2014, respectively, under note agreements with certain shareholders and a line of credit. In addition, the Company borrowed $5.0 million during the year ended December 31, 2014 under the April 2014 Credit Facility. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future.
	Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the issuance of debt, and revenues from clinical laboratory testing through contracted partners. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant net revenues to achieve and sustain income from operations.
	As of December 31, 2014, cash and cash equivalents totaled approximately $5.4 million. On February 13, 2015, the Company received cash proceeds of approximately $9.1 million as a result of the closing of a second public offering, net of underwriting discounts and additional underwriting costs incurred. Subsequent to the closing of the second public offering on February 13, 2015, additional cash proceeds of approximately $6.7 million were received from the exercise of warrants sold in such offering (see Note 21). Management believes that its cash resources should be sufficient to support currently forecasted operations through at least the next twelve months. Management expects that the Company may need additional financing in the future to execute on its current or future business strategies beyond the next twelve months. Until the Company can generate significant cash from operations, the Company expects to continue to fund its operations with the proceeds of offerings of the Company’s equity and debt securities. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all. In addition to test revenues, such financing may be derived from one or more of the following types of transactions: debt, equity, product development, technology licensing or collaboration.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. Summary of Significant Accounting Policies
	Basis of Presentation
	The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.
	Use of Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to inventories, long-lived assets, convertible debt, derivative liabilities, income taxes, and stock-based compensation. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
	Reverse Stock Split and Change in Par Value of Common Stock and Preferred Stock
	In July 2013, in conjunction with its reincorporation in the state of Delaware, the Company initiated par values for preferred and common shares equal to $0.0001. In November 2013, the Company effected a 1:14 reverse stock split for all common shares. All references to share and per share amounts in the financial statements and accompanying notes to the financial statements have been retroactively restated to reflect the 1:14 reverse stock split and the change in par value.
	Revenue Recognition
	Revenue is recognized in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. For contract partners, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, the Company considers whether there is sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is limited evidence of payment history at the time the tests are completed, the Company recognizes revenue equal to the amount of cash received until such time as reimbursement experience can be established.
	The Company’s main source of revenue for the year ended December 31, 2013, and a significant source of revenue for the year ended December 31, 2014, is through contracted partners. This revenue is derived from clinical laboratory testing performed in the Company’s laboratories under agreements with such partners. As there is a contractually agreed upon price, and collectability from the partners is reasonably assured, revenues for these tests are recognized at the time the test is completed.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company places its cash and cash equivalents with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC). At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to any significant credit risk.
	Fair Value Measurement
	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. See Note 5 for further details about the inputs and assumptions used to determine fair value measurements.
	Concentration of Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company has not experienced losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.
	In 2012, the Company launched commercial operations in partnership with a commercial partner, Clarient Diagnostic Services, Inc. (“Clarient”), a GE Healthcare Company. During the years ended December 31, 2013, the final year of this partnership, and December 31, 2014, when subsequent cash collections were made, 10% and 6%, respectively, of the revenues earned were billed through this relationship.
	In 2013, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, Dana-Farber Partners Cancer Care, Inc. (“Dana-Farber”). For the years ended December 31, 2013 and 2014, 77% and 32%, respectively, of the revenues earned were billed through this relationship. In addition, 100% and 72% of the receivables were due from Dana-Farber at December 31, 2013 and 2014, respectively.
	In 2014, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, The University of Texas MD Anderson Cancer Center (“MD Anderson”). For the year ended December 31, 2014, 2% of the revenues earned were billed through this relationship. In addition, 28% of the receivables were due from MD Anderson at December 31, 2014.
	Concentrations of credit risk with respect to revenues and accounts receivable are primarily limited to certain clients including Clarient, Dana-Farber, and MD Anderson, and geographies to which the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. For the year ended December 31, 2013, revenues derived from clients within the states of Massachusetts, California, and Texas accounted for approximately 77%, 22% and 1%, respectively, of total revenues.  For the year ended December 31, 2014, revenues derived from clients within the states of Massachusetts, California, and Texas accounted for approximately 32%, 15% and 34%, respectively, of total revenues.
	All of the Company’s sales for all periods presented were generated in the United States of America.
	Certain components used in the Company’s current or planned products are available from only one supplier, and substitutes for these components cannot be obtained easily or would require substantial design or manufacturing modifications or identification and qualification of alternative sources.
	Accounts Receivable
	Accounts receivable are carried at original invoice amounts, less an estimate for doubtful receivables, based on a review of all outstanding amounts on a periodic basis. The estimate for doubtful receivables is determined from an analysis of the accounts receivable on a quarterly basis, and is recorded as bad debt expense. As the Company only recognizes revenue to the extent collection is expected and reasonably assured, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the statement of operations and comprehensive loss. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of December 31, 2013 and 2014, management determined that all of the amounts recorded as accounts receivable were collectible, and no allowance for doubtful accounts was needed.
	Inventories
	Inventories are valued at the lower of cost or market value. Cost is determined by the average cost method. The Company records adjustments to its inventory for estimated obsolescence or diminution in market value equal to the difference between the cost of the inventory and the estimated market value. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
	Fixed Assets
	Fixed assets consist of machinery and equipment, furniture and fixtures, computer equipment and software, leasehold improvements, capital leased equipment and construction in process. Fixed assets are stated at cost less accumulated depreciation and amortization. Additions, improvements, and major renewals are capitalized. Maintenance, repairs, and minor renewals are expensed as incurred. Depreciation is determined using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Leasehold improvements are amortized over the life of the lease or the asset, whichever is shorter. Depreciation expense for the years ended December 31, 2013 and 2014 was approximately $267,000 and $251,000, respectively.
	Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in the estimates of future cash flows to determine recoverability of these assets. If the assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.
	Warrant Liability
	Warrants for shares that are contingently redeemable and for which the exercise price is not fixed are classified as liabilities on the accompanying balance sheets and carried at their estimated fair value, determined through use of a Black-Scholes valuation model. As of and for the years ended December 31, 2013 and 2014, the Company evaluated and concluded that the fair value obtained from the Black-Scholes method of valuing the warrant liability does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. At the end of each reporting period, any changes in fair value are recorded as a component of other income (expense). As of the closing of the Company’s IPO on February 10, 2014, the exercise price underlying the majority of the Company’s outstanding warrants was fixed and the fair value of those warrants was reclassified to shareholders’ deficit, while a preferred stock warrant to purchase an equivalent of 1,587 shares of common stock remains liability-classified at December 31, 2014.
	Stock-based Compensation
	The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock option awards on the date of grant using the Black-Scholes option pricing model (“Black-Scholes valuation model”), while the fair value of restricted stock unit awards is determined by the Company’s stock price on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises these estimates in subsequent periods if actual forfeitures differ from those estimates. See additional information in Note 13.
	The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of equity instruments issued to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. These awards are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods based on the fair value of the options at the end of each period.
	Calculating the fair value of stock-based awards requires the input of highly subjective assumptions into the Black-Scholes valuation model. Stock-based compensation expense is calculated using the Company’s best estimates, which involves inherent uncertainties, and the application of management’s judgment. Significant estimates include the fair value of the Company’s common stock at the date of grant for awards granted prior to its IPO, the expected life of the stock option, stock price volatility, risk-free interest rate and forfeiture rate.
	Research and Development
	Research and development costs are expensed as incurred. The amounts expensed in the years ended December 31, 2013 and 2014 were approximately $3,087,000 and $4,498,000, respectively, which includes salaries of research and development personnel.
	Income Taxes
	The Company provides for income taxes utilizing the liability method. Under the liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and tax bases of assets and liabilities and for the expected future tax benefit to be derived from tax credits. Tax rate changes are reflected in the computation of the income tax provision during the period such changes are enacted.
	Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year operating loss, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2013 and 2014, and therefore has not recognized any income tax benefit or expense in the periods presented.
	ASC 740, Income Taxes (“ASC 740”), clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	The Company recognizes interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties for income taxes on the balance sheets at December 31, 2013 and 2014, and the Company has not recognized interest and/or penalties in the statements of operations for the years ended December 31, 2013 and 2014.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance that requires netting unrecognized tax benefits against deferred tax assets for a loss or other carryforward that would apply in settlement of uncertain tax positions. This guidance is effective for annual reporting periods beginning after December 15, 2013, and was effective for the Company’s fiscal year beginning January 1, 2014. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.
	In May 2014, the FASB issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
	In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.
	In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
	In November 2014, the FASB issued authoritative guidance requiring entities to consider all of a hybrid instrument’s stated and implied substantive terms and features, including any embedded derivative features being evaluated for bifurcation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

Fair_Value_Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Measurement	5. Fair Value Measurement
	Warrant Liability Derivatives
	The Company classified the fair value measurements of the Company’s warrant liability derivatives as Level 3 in all periods presented. The Company adjusted the carrying value of the warrants classified as liabilities until the completion of its IPO on February 10, 2014, at which time the exercise price was fixed at $10.00 per share and the fair value of the warrants was reclassified to shareholders’ deficit, except for a warrant for 1,587 preferred shares that remains outstanding at December 31, 2014 (see Note 2).
	As of December 31, 2013, the aggregate common stock warrant liability of approximately $2,132,000 was estimated using a probability weighted Black-Scholes valuation model with the following assumptions for both the five-year and two-year common stock warrant terms separately:
		Five-year term			Two-year term
	Stock price	$  1.48 – 7.69			$  1.48 – 7.69
	Exercise price	$  1.48 – 7.69			$  1.48 – 7.69
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.73	%		0.38	%
	Expected life (in years)		5			2
	Expected volatility		100	%		90	%
	At December 31, 2013 the values of both the five-year and two-year common stock warrants using the probability weighted Black-Scholes valuation models accounted for a probability of 75%, while a fair value of $0 was weighted 25%.
	As of closing of the Company’s IPO on February 10, 2014, the aggregate common stock warrant liability of approximately $2,476,000 was estimated using a Black-Scholes valuation model with the following assumptions for both the five-year and two-year common stock warrant terms separately:
		Five-year term			Two-year term
	Stock price	$	8.91		$	8.91
	Exercise price	$	10		$	10
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.48	%		0.32	%
	Expected life (in years)		5			2
	Expected volatility		90	%		90	%
	The fair value attributed to the common and preferred share warrants as of December 31, 2013 and 2014 is as follows:
		Fair Value Measurements Using
		Quoted Prices			Significant
		in Active			Other			Significant
		Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)
	Liabilities
	Warrant Liability at December 31, 2013		—			—			2,140,532
	Warrant Liability at December 31, 2014		—			—			1,070
	The following table includes a summary of changes in the fair value of the common and preferred share warrants for the years ended December 31, 2013 and 2014:
		Fair Value Measurements
		at Reporting Date Using
		Significant Unobservable
		Inputs (Level 3)
	Balance at December 31, 2012	$	981,747
	Warrant liability incurred in 2013		2,322,042
	Change in fair value included in expense in 2013		(782,112	)
	Warrant liability reclassified to additional paid-in capital in 2013		(381,145	)
	Balance at December 31, 2013		2,140,532
	Warrant liability incurred in 2014		135,222
	Change in fair value included in expense in 2014		200,936
	Warrant liability reclassified to additional paid-in capital in 2014		(2,475,620	)
	Balance at December 31, 2014	$	1,070
	The change in the estimated fair value of the total liability outstanding for all outstanding warrants of approximately $782,000 and ($201,000) was recognized as a non-cash gain/(loss) and included in total other income/(expense) in the Company’s statements of operations and comprehensive loss for the years ended December 31, 2013 and 2014, respectively.
	Other Fair Value Measurements
	In connection with the closing of the Company’s IPO on February 10, 2014, the IPO’s underwriters were granted a 45 day option to purchase up to 285,000 shares of common stock to cover overallotments with a grant date fair value of $202,143, which was not exercised. Additionally, certain designees of the representative of the underwriters were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock with a grant date fair value of $544,116. The fair values of these stock option and common stock warrants were estimated using Black-Scholes valuation models with the following assumptions:
		Options			Warrants
	Stock price	$	8.91		$	8.91
	Exercise price	$	9.3		$	12.5
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		0.07	%		1.46	%
	Expected life (in years)		0.12			5
	Expected volatility		70	%		90	%
	The estimated grant date fair values of these non-cash equity classified instruments were recorded as an offset to additional paid-in capital within common stock issuance costs.
	In connection with the closing of the April 2014 Credit Facility on April 30, 2014, the lender was granted a warrant to purchase 52,966 shares of common stock with a 10 year term and an estimated grant date fair value of $233,107 (see Note 7). The fair value of this warrant was estimated using a Black-Scholes valuation model with the following assumptions:
	Stock price	$	4.74
	Exercise price	$	4.72
	Expected dividend yield		0	%
	Discount rate-bond equivalent yield		2.67	%
	Expected life (in years)		10
	Expected volatility		110	%
	The estimated grant date fair value of this non-cash equity classified instrument was recorded as a discount to outstanding debt and is amortized to interest expense utilizing the effective interest method over the underlying term of the loan.
	The estimated fair value of the April 2014 Credit Facility at December 31, 2014 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs (see Note 7).

Balance_Sheet_Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	6. Balance Sheet Details
	The following provides certain balance sheet details:
		December 31,		December 31,
		2013		2014
	Fixed Assets
	Machinery and equipment	$	2,761,560	$	2,922,303
	Furniture and office equipment		209,844		209,844
	Computer equipment and software		681,508		681,508
	Leasehold improvements		373,653		506,328
	Financed equipment		677,000		878,447
	Construction in process		12,299		72,172
			4,715,864		5,270,602
	Less accumulated depreciation and amortization		4,356,977		4,608,180
	Total fixed assets, net	$	358,887	$	662,422
	Accrued Liabilities
	Accrued interest	$	524,885	$	33,125
	Accrued payroll		125,299		82,241
	Deferred wages		1,377,987		—
	Accrued vacation		213,601		276,574
	Accrued bonuses		—		302,763
	Other		286		4,130
	Total accrued liabilities	$	2,242,058	$	698,833
	As of December 31, 2013, the Company incurred $538,318 in costs directly associated with its IPO, which are reflected on the Company’s balance sheet as a component of prepaid expenses and other current assets. A liability of $328,221 for associated unpaid invoices is recorded as a component of accounts payable at December 31, 2013. As of December 31, 2014, a balance of $1,211,896 of such costs, in addition to underwriting discounts of $1,330,000 and an aggregate $746,259 of associated stock option and restricted stock awards, are offset against additional paid-in capital as a result of the closing of the Company’s IPO on February 10, 2014 (see Note 2).
	Costs associated with the Company’s February 2015 public offering totaling $63,111 were incurred during the year ended December 31, 2014, which are reflected on the Company’s balance sheet as a component of prepaid expenses and other current assets at December 31, 2014. A liability of $63,111 for associated unpaid invoices is recorded as a component of accounts payable at December 31, 2014.

April_2014_Credit_Facility

April 2014 Credit Facility	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
April 2014 Credit Facility	7. April 2014 Credit Facility
	On April 30, 2014, the Company received net cash proceeds of approximately $4,927,000 pursuant to the execution of its April 2014 Credit Facility with Oxford Finance LLC.  A second term loan of up to a principal amount of $5 million will be funded at the Company’s request prior to December 31, 2015, subject to the achievement of product and services revenues of at least $9 million for the trailing six months, with such six-month period ending no later than November 30, 2015.  Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lenders a facility fee of $50,000 in conjunction with the funding of the first term loan. Another $50,000 facility fee will be due and payable to the lenders on the funding date of the second term loan (if such date occurs). The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property.  Each term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) 7.95% or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the applicable term loan, plus (b) 7.71%, such rate to be fixed at the time of borrowing. The first term loan bears interest at an annual rate of 7.95%. The Company is required to make interest-only payments on the first term loan through February 1, 2016 if the funding date of the second term loan occurs before June 30, 2015, or through August 1, 2015 otherwise. If the Company requests and the lenders fund the second term loan, the Company is required to make interest-only payments on the second term loan through February 1, 2016 if the funding date of the second term loan occurs before June 30, 2015, or through the seventh month following the funding date of the second term loan otherwise. All outstanding term loans under the April 2014 Credit Facility will begin amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lenders in consecutive monthly installments following such interest-only period. The first term loan under the April 2014 Credit Facility matures on July 1, 2018, and the second term loan matures on the first day of the 29th month following the end of the applicable interest-only period. Upon repayment of each term loan, the Company is also required to make a final payment to the lenders equal to 5.50% of the original principal amount of such term loan funded.   At its option, the Company may prepay the outstanding principal balance of the term loans in whole but not in part, subject to a prepayment fee of 3% of any amount prepaid if the prepayment occurs on or prior to April 30, 2015, 2% of the amount prepaid if the prepayment occurs after April 30, 2015 but on or prior to April 30, 2016, and 1% of any amount prepaid after April 30, 2016.
	The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries the Company creates in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on the Company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loans under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, the Company’s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $250,000.
	A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014 (see Note 5). Additional warrants for shares of the Company’s common stock will be issued upon execution of the second term loan under the April 2014 Credit Facility in an amount equal to 5.0% of the funded amount divided by the exercise price, which will be equal to the lower of (i) the closing price per share of the Company’s common stock on the NASDAQ on the date prior to the funding date of the second term loan or (ii) the ten-day average closing price per share prior to the funding date of the second term loan. Issuance costs of $73,104 associated with the first term loan under the April 2014 Credit Facility were deducted from the gross proceeds by the lender and were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of $4,926,896. Other issuance costs of $28,932 directly related to the April 2014 Credit Facility but not associated with the lender were recorded as a component of other non-current assets in the Company’s balance sheet. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs are amortized to interest expense utilizing the effective interest method over the underlying term of the loan. The total amount of interest expense recorded during the year ended December 31, 2014 related to the April 2014 Credit Facility was $380,264. Approximately $61,000 related to accretion of the discount was recognized as interest expense during the year ended December 31, 2014, with approximately $245,000 remaining unamortized and reflected as a discount to the debt. The April 2014 Credit Facility bears an effective annual interest rate of 10.81% at both April 30, 2014 and December 31, 2014.

Line_of_Credit

Line of Credit	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Line of Credit	8. Line of Credit
	In July 2013, the Company entered into a revolving line of credit with UBS Bank USA in the initial amount of $1.5 million. Interest accrued daily on the outstanding balance and was paid monthly at a variable rate which, as of December 31, 2013, was 2.75% over the 30 day LIBOR rate or a nominal annual interest rate of 2.92%. As of December 31, 2013, the amount outstanding under this revolving line of credit was approximately $2.0 million. Subsequent to December 31, 2013, the maximum amount of the line of credit was increased to approximately $2.6 million. Five of the Company’s affiliated parties guaranteed the loan and pledged financial assets to the bank to secure their guaranties, as approved by the Company’s Board of Directors. In return, the Company issued common stock warrants to the guarantors. The number of shares subject to the common stock warrants was determined by dividing the warrant coverage amount, which is 50% of the fair market value of the collateral provided by the respective guarantors to secure their respective guaranty obligations to the bank, by the exercise price set at the price per share of the Company’s common stock sold in its IPO. See Note 5 for further discussion of the warrant liabilities. The Company entered into an agreement with the guarantors that provided for reimbursement of any amounts paid by them on their guaranties. This reimbursement obligation was secured by a security interest in the Company’s assets.
	In connection with the closing of the Company’s IPO on February 10, 2014, the current outstanding balance under the line of credit of $2,346,000 plus accrued interest of $27,043 was paid in full, and the exercise price of the warrants associated with the $2,578,104 of collateral provided was fixed at $10.00 per share for an aggregate 128,903 shares of common stock, with associated derivative warrant liabilities of $513,603 reclassified to additional paid-in capital.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes Payable	9. Notes Payable
	The following is a summary of the Company’s short-term and long-term debt obligations:
		December 31,
		2013			2014
	Secured convertible note to a major shareholder. As of February 10, 2014, the secured convertible note was converted into common shares. (“2008 Convertible Note”) (See Note 10)	$	1,400,000		$	—
	Unsecured convertible notes, issued under a note and warrant purchase agreement dated as of June 28, 2013, net of discounts related to warrants aggregating $874,158 and $0 at December 31, 2013 and 2014, respectively. Includes notes of $2,505,000 and $0 to a major shareholder at December 31, 2013 and 2014, respectively. As of February 10, 2014, the unsecured convertible notes were converted into common shares. (“2013 Convertible Bridge Notes”) (See Note 10)		4,115,842			—
	Secured term loan agreement, net of discounts related to warrants and lender fees aggregating $0 and $245,484 at December 31, 2013 and 2014, respectively. ("April 2014 Credit Facility") (see Note 7)		—			4,754,516
	Other debt discount. As of February 10, 2014, the remaining unamortized portion of the other debt discount was reclassified to interest expense. (See Notes 8 and 10)		(315,243	)		—
	Total notes payable		5,200,599			4,754,516
	Less current portion		5,200,599			—
	Long-term portion	$	—		$	4,754,516
	The Company was unable to make principal and interest payments on all outstanding notes payable and convertible notes payable except for the non-current balance of the 2013 Convertible Bridge Notes prior to the conversion of certain of the notes as of June 28, 2013. None of the lenders had sought any remedy for this default prior to the conversion of the notes as of June 28, 2013.
	On June 28, 2013, approximately $20,231,000 of outstanding notes payable and $2,581,000 of accrued interest were converted into 42,245,834 preferred shares, in accordance with the provisions of the debt conversion agreements of that date.
	In connection with the closing of the Company’s IPO on February 10, 2014, (i) the $1,400,000 principal amount and $233,982 of accrued interest related to the 2008 Convertible Note were converted at $10.00 per share into a total of 163,399 shares of common stock, (ii) the $5,165,000 principal amount and $313,017 of accrued interest related to the 2013 Convertible Bridge Notes were converted at $10.00 per share into a total of 547,794 shares of common stock, and (iii) derivative warrant liabilities of $1,562,968 associated with an aggregate of 258,249 common stock warrants related to the 2013 Convertible Bridge Notes were reclassified to additional paid-in capital when their underlying exercise price was fixed at $10.00 per share.
	Total interest expense incurred for all notes, convertible notes, and the line of credit, including amortization of debt discounts, for the years ended December 31, 2013 and 2014 was approximately $1,964,000 and $1,768,000, respectively, of which approximately $516,000 and $88,000 was recorded as accrued interest as of December 31, 2013 and 2014, respectively.

Convertible_Notes_and_Warrants

Convertible Notes and Warrants	12 Months Ended
	Dec. 31, 2014
Temporary Equity Disclosure [Abstract]
Convertible Notes and Warrants	10. Convertible Notes and Warrants
	Preferred Shares
	Goodman Note
	During April 2005, the Company entered into an unsecured loan agreement for $15,000,000 (the “Goodman Note”). The note required interest payments and principal settlement upon maturity at the earliest of (a) April 20, 2010, (b) the Company being acquired, or (c) the Company having a change in control, other than through the sale of preferred shares.
	During January 2009, the Company entered into an amendment and restatement of the unsecured amended loan, whereby the parties agreed that the principal amount would be reduced to $3,000,000. The amended and restated unsecured note accrued interest at a variable rate per annum based on prime plus 25 basis points. 25% of the accrued interest was due and payable quarterly in arrears on the last business day of each three-month quarter beginning February 1, 2009. The remaining 75% of the accrued interest was not to be compounded by becoming part of the principal, and was due and payable in a lump-sum payment on the maturity date. The principal and any interest amounts that remain outstanding was set to mature at the earlier of (a) April 20, 2010, or (b) the date immediately prior to the Company’s closing of an acquisition or asset transfer as defined by the Company’s amended and restated articles of incorporation.
	In conjunction with the 2009 amendment, the Company issued a warrant to purchase preferred shares issued in the first equity financing to occur subsequent to the execution of the note, and in which the Company receives at least $2,000,000 in gross aggregate proceeds. The exercise price of the warrant would have been equal to the per share price of preferred shares sold in that equity financing, and the number of shares that may have been exercised was equal to 10% of the principal amount of the convertible loan divided by the exercise price. Early termination of the warrant could occur upon an IPO, or if the Company was acquired. The holder of the warrant was to be given 20 days advance notice of such an event, and the warrant would terminate if not exercised before the date of the event.
	A qualifying equity financing occurred during February 2009, which set the warrant exercise price at $0.60 per share.
	During May 2010, the Company entered into a second amendment and restatement of the Goodman Note in order to extend the maturity date and amend the timing of payments to be made to the lender and to secure the Company’s obligations under the note. The secured amended and restated note accrued interest at a per annum fixed rate of 3.25% and was due and payable quarterly in arrears on the last business day of each three-month quarter beginning May 1, 2010. On the effective date of the second amendment, the Company paid the lender $750,000 which was applied to the principal balance of $3,000,000. Beginning May 1, 2010, principal payments were due and payable quarterly in advance. For principal payments due and payable during the period of May 1, 2010 through January 31, 2011, the quarterly principal payment was equal to $45,000; for principal payments due and payable during the period of February 1, 2012 through January 31, 2014, the quarterly principal payment was equal to $90,000; and for principal payments due and payable during the period of February 1, 2014 through the maturity date, the quarterly principal payment was equal to $150,000. In addition to the $750,000 principal paid on the effective date of the amendment, the Company paid principal payments of $135,000 and $180,000 during the years ended December 31, 2010 and 2011, respectively. No principal payments were made during the years ended December 31, 2012 or 2013.
	As of June 28, 2013 the holder of the Goodman Note agreed to convert the total principal balance owed under the Goodman Note of $1,935,000 and accrued interest of approximately $105,000 into 3,777,324 preferred shares at a conversion price of $0.54 per share. Although the conversion price of the debt was greater than the value of the preferred shares at the time of conversion, the Company did not record a gain on the conversion under the troubled debt restructuring accounting guidance since the transaction occurred between related parties, and thus, was treated as a capital transaction. As of the closing of the Company’s IPO on February 10, 2014, such shares of preferred stock automatically converted into 89,936 shares of common stock.
	In July 2013, in connection with this conversion, the Company issued to such beneficial owner a warrant to purchase 23,809 shares of common stock at an exercise price of $10.00 per share, which was set at the price of the Company’s common stock sold in the Company’s IPO. The warrants are exercisable for a two-year period beginning with the closing of the Company’s IPO on February 10, 2014. In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrants were initially recorded at their fair value and were then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For the warrants for common shares issued under the Goodman Note agreement, the Company used a probability weighted Black-Scholes valuation model. The fair value of the Goodman Note warrants was approximately $62,000 at December 31, 2013 and was included in warrant liabilities until the underlying exercise price was fixed at the closing of the Company’s IPO on February 10, 2014, when the warranty liability balance of approximately $95,000 was reclassified to additional paid-in capital (see Notes 2 and 5).
	2008 Convertible Note
	In December 2008, the Company issued the 2008 Convertible Note in the principal amount of $1,400,000 which was secured by all assets of the Company to an affiliate of a major shareholder. The 2008 Convertible Note accrued interest at a variable rate based on prime per annum payable at maturity, and matured at the earliest occurrence of, (a) the passing of 48 months from inception of the note, (b) the closing date of an acquisition or asset transfer as defined by the note, or (c) the closing date of the issuance and sale of shares of common stock of the Company in the Company’s IPO.
	Upon the closing of a sale by the Company of its preferred shares in which the Company received an aggregate of at least $20,000,000 in cumulative gross proceeds, including conversion of the convertible loan amount before the maturity date, the unpaid principal and accrued interest would automatically be converted into the number of preferred shares, of the series sold by the Company in such sale, equal to the unpaid principal and accrued interest divided by the per share purchase price of the preferred shares in such sale. The 2008 Convertible Note may have also been converted before the maturity date at the option of the holder at the closing of an equity financing involving the sale of the Company’s preferred shares in which the Company received an aggregate of at least $2,000,000 in cumulative gross proceeds, with a conversion price equal to the per share price included in that equity financing. In July 2013, the Company amended the 2008 Convertible Note to provide that all principal and accrued interest on the note would automatically convert into common stock upon the closing of an IPO at the price per share at which common stock is sold in such IPO.
	Issued with the 2008 Convertible Note was a warrant to purchase preferred shares issued in the first equity financing to occur subsequent to the execution of the 2008 Convertible Note, and in which the Company would have received at least $2,000,000 in gross aggregate proceeds. The exercise price of the warrant would have been equal to the per share price of preferred shares sold in that equity financing, and the number of shares that may have been exercised was equal to 10% of the principal amount of the convertible loan divided by the exercise price. Early termination of the warrant could occur upon an IPO or if the Company was acquired. The holder of the warrant was to be given 20 days advance notice of such an event, and the warrant would terminate if not exercised before the date of the event.
	A qualifying equity financing occurred during February 2009, which set the 2008 Convertible Note conversion price and the warrant exercise price at $0.60 per share. In connection with the closing of the Company’s IPO on February 10, 2014, the $1,400,000 principal amount and $233,982 of accrued interest related to the 2008 Convertible Note were converted at $10.00 per share into a total of 163,399 shares of common stock (see Note 2).
	2011 Convertible Bridge Notes
	In February 2011, the Company executed a note and warrant purchase agreement with a major shareholder’s affiliates. In exchange for a series of loans in an aggregate amount equal to $5,000,000 over a period through September 1, 2011, the Company issued the 2011 Convertible Bridge Notes and warrants to purchase preferred shares. The aggregate amount was subsequently raised to $6,000,000 and then $15,000,000 during the year and the funding period was first extended to February 2012 and then to December 2012. Other investors, including related parties, also became party to this arrangement and purchased 2011 Convertible Bridge Notes and warrants.
	All unpaid principal and interest outstanding was initially payable on December 31, 2011. During 2012, the maturity date was extended to December 31, 2012. The 2011 Convertible Bridge Notes were secured by virtually all of the assets of the Company. The 2011 Convertible Bridge Notes accrued interest at 8%, payable at maturity. The number of preferred shares for which the warrants were exercisable was determined by dividing the warrant coverage amount, which was 20% of the principal amount of the notes issued under the agreement, by the exercise price.
	Upon the closing of the sale by the Company of its preferred stock in which the Company received an aggregate of at least $20,000,000 in cumulative gross proceeds, including conversion of the 2011 Convertible Bridge Notes, before the maturity date, the unpaid principal and accrued interest would automatically have been converted into the number of preferred shares, of the series sold by the Company in such sale, equal to the unpaid principal and accrued interest divided by the per share purchase price of the preferred shares in such sale. At any time before the maturity date the investor could elect to convert all or any amount of the unpaid principal and accrued interest into the Company’s Series A preferred shares at $0.54 per share. Early termination of the warrants could occur upon an IPO or if the Company was acquired. The holders of the warrants were to be given 20 days advance notice of such an event, and the warrants would terminate if not exercised before the date of the event.
	In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrants were initially recorded at their fair value and were then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments issued under the note and warrant purchase agreement dated February 2011, the Company used the Black-Scholes valuation model. The Company recorded approximately $1,400,000 related to the fair value of the warrants at the date of issuance, as a discount to the carrying value of the 2011 Convertible Bridge Notes, accreted as interest expense over the life of the debt. The Company valued the warrants at the date of each issuance using the Black-Scholes valuation model with the following underlying assumptions: contractual term of 5 years, an underlying preferred share price between $0.25 and $0.54, an exercise price of $0.54, an average risk-free interest rate between 0.70% and 2.26%, a dividend yield of 0%, and volatilities between 100.0% and 105.0%. The discount was fully accreted as of December 31, 2012.
	As of December 31, 2012, the Company had issued the 2011 Convertible Bridge Notes with an aggregate principal amount of approximately $12,336,000. No further note or warrant issuances were made under this agreement during the year ended December 31, 2013. As of December 31, 2012, the Company was in default for payment on the 2011 Convertible Bridge Notes, and no principal payments were made in 2013 prior to their conversion. As of June 28, 2013 the investors under these notes elected to convert the total principal balance owed under the 2011 Convertible Bridge Notes of approximately $12,336,000 and accrued interest of approximately $1,832,000 into 26,237,611 preferred shares at a conversion price of $0.54 per share. Upon the conversion, the exercise price of the related warrants was set at $0.54 per share, and the $236,799 fair value of the warrants was reclassified into additional paid-in capital as of June 28, 2013. Although the conversion price of the debt was greater than the value of the preferred shares at the time of conversion, the Company did not record a gain on the conversion under the troubled debt restructuring accounting guidance since the transaction occurred between related parties, and thus, was treated as a capital transaction. As of the closing of the Company’s IPO on February 10, 2014, such shares of preferred stock automatically converted into 624,705 shares of common stock.
	2012 Revolver Notes
	On January 13, 2012, the Company executed a note and warrant purchase agreement with several shareholders, including a major shareholder, calling for (in addition to the issuance of certain related warrants) the issuance of a series of 2012 Revolver Notes to be issued between January 13, 2012 and April 5, 2012 totaling up to $1,750,000, with an original maturity date in April 2012. The 2012 Revolver Notes were amended on April 5, 2012 to extend the maturity date to May 31, 2012 or July 31, 2012, depending on certain milestones, and to allow the Company to issue up to $5,000,000 in notes payable under this agreement, as needed. The 2012 Revolver Notes were amended again on November 8, 2012 to increase the amount of notes payable the Company could issue to $8,000,000, and to provide that all notes issued under this agreement would have the same maturity date of either November 30, 2012 or December 31, 2012, depending on certain milestones. The 2012 Revolver Notes accrued interest at 10%, payable at maturity.
	Beginning on the closing of the sale by the Company of its preferred shares in which the Company received an aggregate of at least $20,000,000 in cumulative gross proceeds, the warrants would have been exercisable for preferred shares of the series sold by the Company in such sale, at an exercise price equal to the purchase price per share of the preferred shares sold by the Company in such sale. The number of preferred shares for which the warrants would have been exercisable was determined by dividing the warrant coverage amount, which was 20% of the principal amount of the notes issued under the agreement on the issuance date of such 2012 Revolver Notes, by the exercise price. At any time prior to the maturity date, the investor could elect to convert all or any amount of the unpaid principal and accrued interest into the Company’s Series A preferred stock at $0.54 per share, or if a qualified financing had occurred, at the purchase price per share of the preferred shares sold by the Company in such qualified financing. Early termination of the warrant could occur upon an IPO, or if the Company was acquired. The holders of the warrants were to be given 20 days advance notice of such an event, and the warrants would terminate if not exercised before the date of the event.
	In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrants were initially recorded at their fair value and were then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For the 2012 Revolver Notes and warrants issued under the note and warrant purchase agreement dated January 13, 2012, the Company used the Black-Scholes valuation model. The Company recorded approximately $396,000 related to the fair value of the warrants issued, as a discount to the carrying value of the debt, accreted as interest expense over the life of the debt. The Company valued the warrants at the date of each issuance using the Black-Scholes valuation model with the following underlying assumptions: contractual term of 5 years, an underlying preferred share price between $0.24 and $0.30, an exercise price of $0.54, an average risk-free interest rate between 0.62% and 1.02%, a dividend yield of 0%, and volatility of 105.0%. Approximately $396,000 related to accretion of the discount was recognized as interest expense during the year ended December 31, 2012. The discount was fully accreted as of December 31, 2012.
	As of December 31, 2012, the Company had issued $5,960,000 in 2012 Revolver Notes. The Company was in default for payment of these notes as of December 31, 2012, and no principal payments were made in 2013 prior to conversion. As of June 28, 2013 the investors under the 2012 Revolver Notes elected to convert the total principal balance of approximately $5,960,000 owed under the 2012 Revolver Notes and accrued interest of approximately $645,000 into 12,230,899 preferred shares at a conversion price of $0.54 per share, pursuant to note conversion agreements of that date. Although the conversion price of the debt was greater than the value of the preferred shares at the time of conversion, the Company did not record a gain on the conversion under the troubled debt restructuring accounting guidance since the transaction occurred between related parties, and thus, was treated as a capital transaction. On September 13, 2013, the exercise price of the warrants was fixed at $0.54 per share, and the fair value of the warrant liability of approximately $144,000 on that date was reclassified to additional paid-in capital. As of the closing of the Company’s IPO on February 10, 2014, such shares of preferred stock automatically converted into 291,212 shares of common stock.
	Other
	On September 10, 2012, the Company issued a warrant to its landlord in exchange for a rent deferral through November 30, 2012. The number of Series A preferred shares exercisable under the warrant agreement is determined by dividing the warrant coverage amount of $40,000 by the exercise price. The exercise price of the warrants is $0.60, or, upon the closing of the sale by the Company of its preferred stock in which the Company receives an aggregate of at least $15,000,000 in cumulative gross proceeds, the warrant’s exercise price will be the price per share for which the Company sells its preferred shares in such sale. The term of the warrant is seven years. Early termination of the warrant can occur if the Company is acquired. The holder of the warrant is to be given 20 days advance notice of such an event, and the warrant will terminate if not exercised before the date of the event. The fair value of such liability-classified preferred warrant to purchase an equivalent 1,587 shares of common stock at December 31, 2013 and 2014 is not material to the financial statements.
	As of December 31, 2012, warrants to purchase preferred stock were reflected as a liability on the balance sheet, which was adjusted to estimated fair value at the end of each reporting period over the term of the warrants. These warrants were reclassified to additional paid-in capital during the year ended December 31, 2013. The fair value of the warrant liability for warrants to purchase preferred stock as of December 31, 2012 of approximately $982,000 was estimated using the Black-Scholes valuation model with the following assumptions: contractual term between 3.08 and 4.92 years, an underlying preferred share price of $0.25, an exercise price of $0.54, an average risk-free interest rate between 0.35% and 0.70%, a dividend yield of 0%, and volatility of 105.0%.
	Common Shares
	2013 Convertible Bridge Notes
	The Company executed a convertible note and warrant purchase agreement as of June 28, 2013 with several shareholders, including a major shareholder, relating to the Company’s borrowing as needed of, and issuance of the 2013 Convertible Bridge Notes for, up to $7,000,000. The Company had borrowed $4,990,000 and $5,165,000 as of December 31, 2013 and as of the closing of the Company’s IPO on February 10, 2014, respectively, against the 2013 Convertible Bridge Notes, including $2,505,000 at each date from a major shareholder. As of December 31, 2013, the maturity date of the 2013 Convertible Bridge Notes was May 31, 2014 with the option to extend by the respective note holders for two successive six month periods. The 2013 Convertible Bridge Notes accrued interest at 8.0% per annum, payable at maturity.
	The 2013 Convertible Bridge Notes would automatically convert into the Company’s common stock upon the closing of an IPO of at least $8,000,000 in cumulative gross proceeds, at a price equal to the price per share of the Company’s common stock sold in the IPO. The number of common shares for which the warrants were exercisable was determined by dividing the warrant coverage amount, which was 50% of the principal amount of the notes issued under the agreement, by the exercise price of $10.00, which was the price per share of the Company’s common stock sold in the IPO. The warrants are exercisable for a five-year period beginning with the closing of the Company’s IPO on February 10, 2014. Early termination of the warrants can occur upon any capital reorganization, any reclassification of the capital stock, or an asset transfer or acquisition of the Company. The holders of the warrants are to be given 20 days advance notice of such an event, and the warrants will terminate if not exercised prior to the date of the event.
	In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrants were initially recorded at their fair value and were then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For the warrants for common shares issued together with the 2013 Convertible Bridge Notes, the Company used a probability weighted Black-Scholes valuation model. The Company recorded approximately $1,612,000 related to the fair value of the warrants issued, as a discount to the carrying value of the debt, accreted to interest expense using the effective interest method from the date of issuance over the life of the debt. These warrants to purchase common stock were valued as of their date of issuance, using the following assumptions: exercise price of between $1.48 and $14.28 per share, contractual term of 5 years, a risk-free interest rate between 1.38% and 1.73%, a dividend yield of 0%, and volatility between 100.0%—105.0%. The value of the warrants using the probability weighted Black-Scholes valuation model accounted for a probability between 75% and 80%, while a fair value of $0 was weighted between 20% and 25%. The fair value of the warrants was approximately $1,399,000 at December 31, 2013 and was included in warrant liabilities until the underlying exercise price was fixed at the closing of the Company’s IPO on February 10, 2014, when the warranty liability balance of approximately $1,563,000 was reclassified to additional paid-in capital (see Notes 2 and 5). Approximately $685,000 related to accretion of the discount was recognized as interest expense during the year ended December 31, 2013, with approximately $874,000 remaining unamortized and reflected as a discount to the debt at December 31, 2013. Approximately $928,000 related to accretion and write-off of the discount was recognized as interest expense from January 1, 2014 until the closing of the Company’s IPO on February 10, 2014, when the $5,165,000 principal amount and $313,017 of accrued interest related to the 2013 Convertible Bridge Notes were converted at $10.00 per share into a total of 547,794 shares of common stock (see Note 2).
	Line of Credit
	Five of the Company’s related parties guaranteed the Company’s Line of Credit (see Note 8) and pledged financial assets to the bank to secure their guaranties, as approved by the Company’s Board of Directors. In return, the Company issued common stock warrants to the guarantors. The fair market value of the collateral provided by the respective guarantors until the closing of the Company’s IPO on February 10, 2014 was $2,578,076. The number of shares subject to the common stock warrants was determined by dividing the warrant coverage amount, which was 50% of the fair market value of the collateral provided by the respective guarantors to secure their respective guaranty obligations to the bank, by the exercise price of $10.00, which was set at the price per share of the Company’s common stock sold in its IPO. The warrants are exercisable for a two-year period beginning with the closing of the Company’s IPO on February 10, 2014.
	In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrants were initially recorded at their fair value and were then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For the warrants for common shares issued in connection with the Company’s Line of Credit, the Company used a probability weighted Black-Scholes valuation model. The Company recorded approximately $536,000 related to the fair value of the warrants issued, as a discount to the carrying value of the debt, accreted to interest expense on a straight line basis from the date of issuance over the life of the debt. These warrants to purchase common stock were valued as of their date of issuance, using the following assumptions: exercise price between $1.48 and $14.28 per share, contractual term of 2 years, a risk-free interest rate between 0.38% and 1.38%, a dividend yield of 0%, and volatility between 90.0% and 105.0%. The value of the warrants using the probability weighted Black-Scholes valuation model accounted for a probability of 75%, while a fair value of $0 was weighted 25%. The fair value of the warrants was approximately $390,000 at December 31, 2013 and was included in warrant liabilities until the underlying exercise price was fixed at the closing of the Company’s IPO on February 10, 2014, when the warranty liability balance of approximately $514,000 was reclassified to additional paid-in capital (see Notes 2 and 5). Approximately $139,000 related to accretion of the discount was recognized as interest expense during the year ended December 31, 2013, with approximately $315,000 remaining unamortized and reflected as a discount to outstanding debt at December 31, 2013. Approximately $397,000 related to accretion and write-off of the discount was recognized as interest expense from January 1, 2014 until the closing of the Company’s IPO on February 10, 2014, after which the total outstanding $2,346,000 principal amount and $27,043 of accrued interest were repaid using the net proceeds from the IPO.
	Other
	On September 10, 2013, the Company, as part of a lease amendment for its non-cancellable operating lease for its office, laboratory, and warehouse space at its San Diego, California facility, issued a warrant to its landlord with a coverage amount of $502,605. The warrant is exercisable for a five-year period beginning with the closing of the Company’s IPO on February 10, 2014, when such warrant became exercisable for 50,260 shares of common stock and the exercise price was fixed at $10.00 per share.
	In accordance with guidance applicable to accounting for derivative financial instruments that are accounted for as liabilities, the warrant was initially recorded at fair value and then was re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For the warrant for common shares issued to the landlord, the Company used a probability weighted Black-Scholes valuation model. The Company recorded approximately $309,000 related to the fair value of the warrant issued at issuance in September 2013, as a reduction in deferred rent liability, accreted to rent expense on a straight line basis from the date of issuance over the term of the amended lease. The warrant was valued as of the date of issuance, using the following assumptions: exercise price of between $3.08 and $14.28 per share, contractual term of 5 years, a risk-free interest rate of 1.38%, a dividend yield of 0%, and volatility of 105.0%. The value of the warrant using the probability weighted Black-Scholes valuation model accounted for a probability of 75%, while a fair value of $0 was weighted 25%. The fair value of the warrant was approximately $282,000 at December 31, 2013 and was included in warrant liabilities until the underlying exercise price was fixed at $10.00 per share at the closing of the Company’s IPO on February 10, 2014, when the warranty liability balance of approximately $304,000 was reclassified to additional paid-in capital (see Notes 2 and 5).

Supplier_Financing

Supplier Financing	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Supplier Financing	11. Supplier Financing
	In 2011, the Company purchased certain laboratory equipment under financing agreements with a supplier, a business owned by a member of the Company’s Board of Directors, totaling approximately $256,000. Financing was granted for the purchase of the equipment at a stated interest rate of 0.0%. The Company utilized its average interest rate for 2013 of 8.0% to amortize the payments and record interest expense of approximately $5,000 for the year ended December 31, 2013, utilizing the effective interest expense method. The remaining balance owed under these financing agreements was approximately $66,000 as of December 31 2013 and was due in 2013, and was subsequently paid in full using the net proceeds from the Company’s IPO.
	In 2011, the Company purchased laboratory software under a financing agreement with a supplier for approximately $177,000. This software financing agreement bears an interest rate of 7.4% per annum. The balance owed under these financing agreements was approximately $62,000 at December 31, 2013 and was subsequently paid in full using the net proceeds from the Company’s IPO.
	In 2013 and 2014, the Company obtained third-party financing for certain business insurance premiums. The financing bears an interest rate of 5.95% per annum, and all financing is due within one year. The balances due under these annual financing arrangements were approximately $91,000 and $34,000 as of December 31, 2013 and 2014, respectively.

Shareholders_Deficit

Shareholders Deficit	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Shareholders' Deficit	12. Shareholders’ Deficit
	(a) Common Stock
	On November 1, 2013, the Company effected a 1:14 reverse stock split for all common shares. All references to share and per share amounts in the financial statements and accompanying notes to the financial statements have been retroactively restated to reflect the 1:14 reverse stock split.
	On July 22, 2013, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 14,600,000 to 53,000,000. In addition, on July 30, 2013, the Company assigned a par value to its common shares of $0.0001 in conjunction with its reincorporation in Delaware. The new par value per common share has been retroactively reflected in the financial statements for all periods presented. The authorized number of shares of common stock at December 31, 2013 was 53,000,000. On February 4, 2014, as contemplated by the registration statement covering the Company’s IPO, the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 40,000,000 shares of common stock.
	(b) Preferred Stock
	As of December 31, 2012, all 36,460,000 authorized shares of preferred stock were designated as Series A preferred stock. On July 22, 2013, the Company amended its articles of incorporation to increase the number of authorized preferred shares from 14,600,000 to 100,000,000. In addition, on July 30, 2013, the Company assigned a par value to its preferred shares of $0.0001 in conjunction with its reincorporation in Delaware. The new par value per preferred share has been retroactively reflected in the financial statements for all periods presented. On February 4, 2014, as contemplated by the registration statement covering the Company’s IPO, the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 5,000,000 shares of preferred stock.
	Holders of the Company’s preferred shares were entitled to receive, when and as declared by the Board of Directors and in preference to common shareholders, non-cumulative cash dividends at the rate of 8% per annum of the applicable original issue price on each outstanding preferred share. The original issue price of each share of Series A preferred stock was $0.60. No dividends were declared during 2013 or 2014. Dividends cannot be granted for common shareholders while shares of preferred stock remain outstanding.
	The holders of preferred shares had the right to one vote for each common share into which the preferred shares were convertible. Upon the liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the preferred shareholders would have been paid out an amount equal to the original issue price plus all declared and unpaid dividends. If, upon any liquidation, distribution, or winding up of the Company, and the assets of the Company were insufficient to make payment in full to all holders of preferred shares of the liquidation preference, then such assets would have been distributed among the holders of preferred shares ratably in proportion to the full amounts to which they would be entitled.
	The convertible preferred shares could have been converted into common shares at any time at the option of the holder utilizing the then effective Series A preferred conversion price. All preferred shares would have been automatically converted into common shares utilizing the then effective Series A preferred conversion price upon a) the election of the holders of a majority of the outstanding shares of Series A preferred stock, or b) the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the sale of the Company’s common stock if gross proceeds are at least $20,000,000 and the per share price is at least $25.20.
	The effective conversion price was equal to the original issue price divided by $25.20 and could have been adjusted for dilutive issuances of common shares, common share rights or options, common share splits and combinations, dividends, and distributions. The effective conversion rate would not have been adjusted for issuances of common share options, warrants or rights to employees, directors, or non-employee service providers.
	During the year ended December 31, 2013, 42,245,834 shares of Series A preferred stock were issued for the conversion of approximately $20,231,000 of debt and $2,581,000 of accrued interest, primarily to related parties (see Notes 9 and 10).

Accounting_for_StockBased_Comp

Accounting for Stock-Based Compensation Expense	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Accounting for Stock-Based Compensation Expense	13. Accounting for Stock-Based Compensation Expense
	2007 Equity Incentive Plan
	The 2007 Equity Incentive Plan (“2007 Plan”) authorizes the grant of the following types of awards: (i) nonstatutory stock options, or NSOs, (ii) incentive stock options, or ISOs, (iii) restricted stock awards, (iv) restricted stock unit awards, or RSUs, (v) stock appreciation rights, or SARs, (vi) performance awards, and (vii) other stock awards. Awards may be granted to employees, officers, non-employee board members, consultants, and other service providers of the Company. However, ISOs may not be granted to non-employees. In conjunction with the 1:14 reverse common stock split in November 2013, the number of shares authorized under the 2007 Plan decreased to 178,571 shares. As of December 31, 2013 and 2014, shares available for grant under the 2007 Plan were 77,061 and 86,001, respectively.
	2013 Equity Incentive Plan
	In July 2013, the Company adopted a new stock-based compensation plan entitled the 2013 Equity Incentive Plan (“2013 Plan”). The 2013 Plan authorizes the grant of the following types of awards: (i) nonstatutory stock options, (ii) ISOs, (iii) restricted stock awards, (iv) restricted stock unit awards (“RSUs”), (v) stock appreciation rights, and (vi) performance compensation awards. Awards may be granted to employees, officers, non-employee board members, consultants, and other service providers of the Company. However, ISOs may not be granted to non-employees. The Company has authorized a total of 403,571 shares of common stock for issuance pursuant to awards granted under the 2013 Equity Incentive Plan, subject to an increase of 800,000 shares upon the completion of an IPO, and subject to additional increases every January 1 equal to the lesser of (i) 5% of the Company’s outstanding common stock on such January 1, or (ii) a number of shares determined by the Company’s Board of Directors in its discretion for use on such particular January 1.  On February 10, 2014, in connection with the closing of the Company’s IPO, the number of shares of common stock covered by the 2013 Plan increased by 800,000. As of December 31, 2014, 1,027,846 stock options and RSUs have been granted under the 2013 Plan, and 175,725 shares are available for grant under the 2013 Plan.
	Stock Options
	Options granted under either plan vest over a maximum period of four years and expire ten years from the date of grant. Options generally vest either (i) over four years, 25% on the one year anniversary of the date of grant and monthly thereafter for the remaining three years; or (ii) over four years, monthly vesting beginning month-one after the grant and monthly thereafter. Certain options have been granted which vest 50% on the grant date and monthly thereafter for the remaining two years.
	The fair value of stock options is determined on the date of grant using the Black-Scholes valuation model. For non-performance awards, such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line method. The amount and timing of compensation expense recognized for performance awards is based on management’s estimate of the most likely outcome. The determination of the fair value of stock options is affected by the Company’s stock price, as well as assumptions regarding a number of complex and subjective variables. The volatility assumption is based on a combination of the historical volatility of the Company’s common stock and the volatilities of similar companies over a period of time equal to the expected term of the stock options. The volatilities of similar companies are used in conjunction with the Company’s historical volatility because of the lack of sufficient relevant history for the Company’s common stock equal to the expected term. The expected term of employee stock options represents the weighted-average period the stock options are expected to remain outstanding. The expected term assumption is estimated based primarily on the options’ vesting terms and remaining contractual life and employees’ expected exercise and post-vesting employment termination behavior. The risk-free interest rate assumption is based upon observed interest rates on the grant date appropriate for the term of the employee stock options. The dividend yield assumption is based on the expectation of no future dividend payouts by the Company.
	The assumptions used in the Black-Scholes pricing model for options granted during the years ended December 31, 2013 and 2014 are as follows:
			2013				2014
	Stock and exercise prices		$	5.18			$2.79 - $9.11
	Expected dividend yield			0.00%				0.00%
	Discount rate-bond equivalent yield		1.38% – 1.69%				1.56% – 2.06%
	Expected life (in years)		5.26 – 6.02				5.00 – 6.08
	Expected volatility			105.00%			90.0% – 100.0%
	Expected forfeiture rate		0.00% – 5.00%				0.00% – 5.00%
	Using the assumptions described above, the weighted-average estimated fair value of options granted in 2013 and 2014 were approximately $4.43 and $5.25, respectively.
	A summary of stock option activity for 2013 and 2014 is as follows:
											Average
							Weighted				Remaining
			Number of				Average Exercise				Contractual
			Shares				Price Per Share				Term in Years
	Outstanding at December 31, 2012			63,518			$	4.97				6.2
	Granted			300,438			$	5.18
	Exercised			(4,021	)		$	5
	Cancelled/forfeited/expired			(26,829	)		$	5.2
	Outstanding at December 31, 2013			333,106			$	5.14				9.3
	Granted			647,298			$	6.71
	Exercised			—				—
	Cancelled/forfeited/expired			(74,210	)		$	4.77
	Outstanding at December 31, 2014			906,194			$	6.29				9
	Vested and unvested expected to vest, December 31, 2014			901,882			$	6.28				8.9
	The intrinsic value of options exercised during the year ended December 31, 2013 was $3,450. The intrinsic value of options outstanding at December 31, 2013 and 2014 was $8,204 and $0, respectively.
	The Company received $20,105 in proceeds from stock options exercised during the year ended December 31, 2013. The tax benefit related to stock options exercised during the year ended December 31, 2013 was not significant.
	Further information about the options outstanding and exercisable is as follows:
	Options Outstanding and Exercisable at December 31, 2013
									Weighted
	Weighted								Average
	Average				Total Shares				Contractual				Total Shares
	Exercise Price				Outstanding				Life (in years)				Exercisable
	$	4.62				20,208				7.3				13,731
	$	5.04				12,460				5.5				12,455
	$	5.18				300,438				9.6				110,825
						333,106								137,011
	Options Outstanding and Exercisable at December 31, 2014
									Weighted
	Weighted								Average
	Average				Total Shares				Contractual				Total Shares
	Exercise Price				Outstanding				Life (in years)				Exercisable
	$	2.79				52,500				9.8				—
	$	4.42				103,934				8.8				29,715
	$	5.22				413,962				8.8				241,918
	$	7.5				43,000				9.2				—
	$	8.88				238,500				9.1				—
	$	9.11				54,298				9.1				54,298
						906,194								325,931
	The intrinsic value of options exercisable at December 31, 2013 and 2014 was $5,575 and $0, respectively.
	Restricted Stock
	The fair value of restricted stock awarded under either plan is determined by the closing price of the Company’s common stock on the date of grant. For non-performance awards, such value is recognized as expense over the requisite service period, net of estimated forfeitures, using the straight-line method. The amount and timing of compensation expense recognized for performance-based awards is based on management’s estimate of the most likely outcome.
	In November 2010, the Company issued to a member of the Board of Directors a restricted stock unit award for 390,000 shares of Series BB preferred stock. In November 2011, these RSUs were modified to be redeemable for Series A preferred stock under the same terms and conditions of the original grant. As of the closing of the Company’s IPO on February 10, 2014, 9,285 RSUs with an estimated grant date fair value of $4.62 per share vested in accordance with the terms of the underlying agreement. The common shares underlying this vested RSU award are not yet distributed.
	In March 2011, the Company awarded a restricted stock unit award to a member of the Board of Directors for 428,597 shares of Series BB preferred stock. Also in March 2011, the Company awarded an additional performance-based restricted stock unit award for an estimated 574,108 shares of Series BB preferred stock to the same member. In November 2011, these RSUs were modified to be redeemable for Series A preferred stock under the same terms and conditions of the original grant. The number of shares in the RSUs is based on certain milestones to be achieved. As of the closing of the Company’s IPO on February 10, 2014, 63,866 RSUs with an estimated grant date fair value of $4.62 per share vested in accordance with the terms of the underlying agreements. The common shares underlying these vested RSU awards are not yet distributed.
	The Board of Directors approved a resolution in December 2010, that each January 1 each person (other than two identified individuals) who is serving as a non-employee director on such January 1 shall be automatically granted an annual restricted stock unit award covering a number of common shares equal to 0.25% of the fully diluted outstanding common stock of the Company as of the December 31 immediately preceding such January 1. These RSUs will be granted automatically on each January 1 and will vest in equal monthly installments over 12 months from the date of the grant. Additionally, in January 2012, each person (other than two identified individuals) who is serving as a non-employee director is to be granted a “true up grant” in addition to the annual grant covering a number of common shares equal to 0.25% of the fully diluted outstanding common shares of the Company as of the immediately preceding December 31. These RSUs will vest 100% on the date of the grant. In January 2012, five restricted stock unit awards for a total of 20,930 common shares were granted in accordance with this resolution. In addition, on January 1, 2012, an additional five restricted stock unit awards were granted to non-employee directors for a total of 20,930 common shares, vesting immediately upon grant. Although vested, shares are only delivered on the earlier of (i) the date that is 10 years from the grant date, (ii) the date of a change in control, (iii) the date of termination of the holder from the Company, (iv) the date of death or disability, or (v) the date of an unforeseeable emergency as described in Internal Revenue Code section 409A.
	RSU awards for 8,735 shares of common stock each were granted to three directors and an RSU award for 14,285 shares of common stock was granted to another director, on July 31, 2013. All RSUs awarded in July 2013 have an estimated grant date fair value of $5.60 per share and vest in equal monthly installments over five months beginning August 1, 2013. The common shares underlying these vested RSU awards are not yet distributed.
	In August 2013, 60,712 RSU awards with an estimated grant date fair value of $5.60 per share were granted to certain executive employees. These awards vest 50% on the date of grant, with the remaining 50% vesting in equal monthly installments over twenty-four months beginning August 31, 2013. The common shares underlying the vested portions of these RSU awards are not yet distributed.
On June 12, 2014, the Company’s Board of Directors approved the issuance of 44,496 RSUs with a grant date fair value of $5.35 per share to its Chief Executive Officer pursuant to the 2013 Plan. Vesting of these RSUs may occur based on the Company’s achievement of specified objectives as determined by the Company’s Board of Directors or Compensation Committee, as follows:
		Percentage of
		Overall RSU
		Grant Subject to
		Vesting
Target
Minimum revenue in 2015			25	%
Maximum EBITDA loss in 2015			15	%
Attainment of financial plan for fiscal 2015			20	%
Minimum value of strategic agreements by December 31, 2015			20	%
Implementation of four new diagnostic test panels by December 31, 2015			20	%
Total			100	%
Stock-based Compensation Expense
The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the statement of operations during the periods presented:
		Years Ended December 31,
		2013				2014
Stock Options
Cost of revenues		$	-			$	20,961
Research and development expenses			298,618				163,229
General and administrative expenses			221,726				1,139,309
Sales and marketing expenses			—				76,204
Total expenses related to stock options			520,344				1,399,703
RSUs
Research and development expenses			72,500				30,000
General and administrative expenses			359,677				392,958
Total stock-based compensation		$	952,521			$	1,822,661
As of December 31, 2014, total unrecognized share-based compensation expense related to nonvested stock option and restricted stock awards, adjusted for estimated forfeitures, was approximately $2,735,000 and $50,000, respectively, and is expected to be recognized over a weighted-average period of approximately 2.6 years and 0.6 years, respectively.

Net_Loss_per_Common_Share

Net Loss per Common Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss per Common Share	14. Net Loss per Common Share
	Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the years ended December 31, 2013 and 2014, the outstanding shares of Series A preferred stock, RSUs, convertible debt, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same.
	In November 2013, the Company effected a 1:14 reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse split as if it had occurred on January 1, 2013.
	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:
		For the year ended
		December 31,
		2013		2014
	Series A preferred (number of common stock equivalents)		1,652,851		—
	Preferred warrants outstanding (number of common stock equivalents)		192,262		1,587
	Preferred share RSUs (number of common stock equivalents)		89,647		73,151
	Common warrants outstanding		836,890		609,187
	Notes payable convertible into common shares		1,110,649		—
	Common share RSUs		133,971		178,467
	Common options outstanding		333,106		906,194
	Total anti-dilutive common share equivalents		4,349,376		1,768,586

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
401(k) Plan	15. 401(k) Plan
	The Company sponsors a 401(k) savings plan for all eligible employees. The Company may make discretionary matching contributions to the plan to be allocated to employee accounts based upon employee deferrals and compensation. To date, the Company has not made any matching contributions into the savings plan.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	16. Income Taxes
	For the year ended December 31, 2013 and 2014, the provision for income taxes was calculated as follows:
		For the year ended December 31,
		2013			2014
	Current:
	Federal	$	—		$	—
	State		800			1,506
	Total		800			1,506
	Deferred
	Federal		—			—
	State		—			—
	Total		—			—
	Provision for income tax	$	800		$	1,506
	The following table provides a reconciliation between income taxes computed at the federal statutory rate and the Company’s provision for income taxes:
		For the year ended December 31,
		2013			2014
	Income tax at statutory rate	$	(3,139,368	)	$	(5,393,944	)
	State liability		(321,058	)		(813,039	)
	Permanent items		6,932			14,374
	Stock Compensation		171,003			159,128
	Nondeductible Interest		395,089			399,249
	Expiration of net operating losses		188,316			1,136,317
	Other		(6,723	)		339,636
	Research and development credit		(103,500	)		(127,491	)
	Valuation allowance		2,810,109			4,287,276
	Provision for income tax	$	800		$	1,506
	Deferred income taxes are provided for temporary differences in recognizing certain income and expense items for financial and tax reporting purposes. The deferred tax assets consisted primarily of the income tax benefits from net operating loss carryforwards, deferred rent, and research and development credits. Valuation allowances have been recorded to fully offset deferred tax assets at December 31, 2013 and 2014, as it is more likely than not that the assets will not be utilized.
	At December 31, 2014, the Company had federal net operating loss carryforwards of approximately $124,601,000 expiring beginning in 2020 and California net operating loss carryforwards of approximately $84,764,000 expiring beginning in 2015. California net operating loss carryforwards of approximately $13,655,000, $15,808,000 and $55,301,000 will expire in 2015, 2016, and in 2017 and beyond, respectively. Additionally, at December 31, 2014, the Company had research and development credits of approximately $3,205,000 and $3,087,000 for federal and California purposes, respectively. The federal research and development tax credits will begin to expire in 2018. The California research and development tax credits do not expire.
	For the years ended December 31, 2013 and 2014, the Company has evaluated the various tax positions reflected in its income tax returns for both federal and state jurisdictions, to determine if the Company has any uncertain tax positions on the historical tax returns. The Company recognizes the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. The Company does not recognize uncertain income tax positions if they have less than 50 percent likelihood of being sustained. Based on this assessment, the Company believes there are no tax positions for which a liability for unrecognized tax benefits should be recorded as of December 31, 2013 or 2014. The Company is subject to taxation in the United States, California and other states. The Company may earn taxable income in some states in future periods for which there are no net operating loss carryforward credits to offset the resulting taxes owed to these states. The Company’s federal filings prior to 2010 and the Company’s state filings prior to 2009 are no longer subject to examination. The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits will not impact the Company’s effective tax rate. The Company is currently not under examination by any taxing authorities and does not believe its unrecognized tax benefits will significantly change in the next twelve months.
	The tax effects of carryforwards that give rise to deferred tax assets consist of the following:
		For the year ended December 31,
		2013			2014
	Net operating loss carryforward	$	43,666,636		$	47,329,815
	Research and development credits		5,114,652			5,242,144
	Accruals and other		742,045			1,216,600
	Deferred rent		176,893			198,945
			49,700,226			53,987,504
	Less valuation allowance		(49,700,226	)		(53,987,504	)
	Net deferred tax assets	$	—		$	—
	Utilization of the domestic net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which on its own or combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future.
	Upon the occurrence of an ownership change under Section 382 of the Code as outlined above, utilization of the net operating loss and research and development credit carryforwards are subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, which could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss or research and development credit carryforwards before utilization. The Company has not yet completed an analysis to determine whether an ownership change has occurred.
	On September 13, 2013, the U.S. Treasury Department released final income tax regulations on the deduction and capitalization of expenditures related to tangible property. These final regulations apply to tax years beginning on or after January 1, 2014, and may be adopted in earlier years. The Company adopted the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property for the tax year beginning on January 1, 2014. The impact of these changes to was not material to the Company’s financial statements or disclosures.

Collaborative_Agreements

Collaborative Agreements	12 Months Ended
	Dec. 31, 2014
Collaborative Arrangement Disclosure [Abstract]
Collaborative Arrangements	17. Collaborative Agreements
	On August 17, 2011, the Company entered into a three year exclusive collaboration agreement with Clarient to collaborate to promote and maximize the commercialization of the Company’s or jointly developed diagnostic tests (together, the “Diagnostic Tests”) in the United States. Clarient is responsible for marketing, providing customer service, and for third party billing on all Diagnostic Tests performed under the agreement, and for performing the professional component of the Diagnostic Tests. The Company is responsible for promoting sales of the Diagnostic Tests in the United States, as well as performing all technical components of all Diagnostic Tests sold by either party.
	Under this agreement, the Company invoices Clarient for the performance of each of the Diagnostic Tests at a contractually agreed-upon rate. Clarient is responsible for billing the patient, provider and/or payer for each completed test, and bears all collection risk related to such billings. Sales of Diagnostic Tests under this agreement did not commence until 2012. The total amount of revenue the Company earned under this agreement was approximately $14,000 and $8,000 for the years ended December 31, 2013 and 2014, respectively.
	The agreement was replaced as of May 2013 to remove exclusivity provisions and to modify the performance obligations of the parties. As a result of the replacement agreement, the Company will be responsible for billing third party payors for tests performed under the Clarient agreement. Revenue derived from the Clarient arrangement after the replacement date is recognized as collected, provided all other revenue recognition criteria are met.
	In January 2013, the Company entered into a research support agreement with Dana-Farber, a not-for-profit tax-exempt organization. The Company is responsible for performing all technical components of the diagnostic tests as ordered by Dana-Farber and recognizes revenue as services are delivered, provided all other revenue recognition criteria are met. The total amount of revenue the Company earned under this agreement was approximately $104,000 and $43,000 for the years ended December 31, 2013 and 2014, respectively.
	In September 2014, the Company entered into a two year research support agreement with MD Anderson, a not-for-profit tax-exempt organization. The Company is responsible for performing all technical components of the diagnostic tests as ordered by MD Anderson and recognizes revenue as services are rendered, provided all other revenue recognition criteria are met. The total amount of revenue the Company earned under this agreement was approximately $3,000 for the year ended December 31, 2014.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	18. Related Party Transactions
	During 2005, the Company executed the Goodman Note in favor of an investor which became a beneficial owner of more than 5% of the Company’s common stock. As of December 31, 2012, the Company had $1,935,000 outstanding on this note. In June 2013, the investor converted the entire principal amount of $1,935,000 and accrued interest of approximately $105,000 due on the Goodman Note into 3,777,324 shares of Series A preferred stock. As of the closing of the Company’s IPO on February 10, 2014, such shares of preferred stock automatically converted into 89,936 shares of common stock.
	During 2008, the Company executed the 2008 Convertible Note with an affiliate of a major shareholder who was a member of the Board of Directors in the amount of $1,400,000. A warrant to purchase preferred shares was issued along with the convertible promissory note (see Notes 9 and 10). In July 2013, the Company amended the 2008 Convertible Note with a principal balance of $1,400,000, held by a related party, to provide that all principal of and accrued interest on the note would automatically convert into common stock upon the closing of an IPO at the price per share at which common stock is sold in such IPO. In connection with the closing of the Company’s IPO on February 10, 2014, the $1,400,000 principal amount and $233,982 of accrued interest related to the 2008 Convertible Note were converted at $10.00 per share into a total of 163,399 shares of common stock (see Note 2).
	As of June 28, 2013, $17,060,000 of principal and $2,339,000 of interest due to affiliates of a major shareholder who was a member of the Board of Directors under several note and warrant purchase agreements was converted into shares of 35,923,845 Series A preferred stock. As of December 31, 2013, the Company had $3,905,000 of such notes payable due to affiliates of this major shareholder (see Notes 9 and 10). In connection with the closing of the Company’s IPO on February 10, 2014, the total balance of outstanding notes payable of $3,905,000 together with $433,821 of accrued interest were converted at $10.00 per share into a total of 433,883 shares of common stock, including 163,399 shares associated with the 2008 Convertible Note (see Note 2).
	As of June 28, 2013, approximately $975,000 of principal and $101,000 of interest due on a portion of notes payable outstanding with members of the Board of Directors under several different note and warrant purchase agreements were converted into 1,993,591 preferred shares (see Notes 9 and 10). As of December 31, 2013 and the closing of the Company’s IPO on February 10, 2014, the Company had approximately $1,479,000 and $1,554,000, respectively, of notes payable outstanding under such note and warrant purchase agreements. In connection with the closing of the Company’s IPO on February 10, 2014, the total aggregate balance of outstanding notes payable of $1,554,000 together with $87,531 of accrued interest were converted at $10.00 per share into a total of 164,104 shares of common stock (see Note 2).
	In September and December 2013, and January 2014, the Company issued common stock warrants to five shareholders who were also affiliates in conjunction with their guarantees on the Company’s borrowings under the Company’s line of credit (see Notes 8 and 10).
	During 2011, the Company entered into two supplier financing arrangements with a business owned by a member of the Board of Directors totaling $256,000, of which $66,000 is outstanding as of December 31, 2013 and was subsequently paid in full using the net proceeds from the Company’s IPO (see Notes 2 and 11).
	A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc. (“Aegea”). On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement with Aegea Biotechnologies, Inc. The total amount of invoices received by the Company from Aegea during the year ended December 31, 2013 was approximately $2,000, which are unpaid and recorded in accounts payable at December 31, 2013 and 2014.
	All of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for total proceeds of $177,500 (see Note 21).
	The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	19. Commitments and Contingencies
	Operating Leases
	The Company leases office, laboratory, and warehouse space at its San Diego, California facility under a non-cancelable operating lease. The initial lease was for an eight-year term expiring in 2012. In November 2011, the Company extended the lease term through October 31, 2018 and expanded the original premises by 9,849 square feet. Under the amended lease, the landlord delivered the expanded premises in May 2013. The Company records rent expense on a straight-line basis over the life of the lease and records the excess of expense over the amounts paid as deferred rent.
	For the years ended December 31, 2013 and 2014, rent expense was approximately $1,143,000 and $1,272,000, respectively. As of December 31, 2012 the Company owed rent in arrears of approximately $185,000, and as of December 31, 2013 and 2014, the Company owed no rent in arrears.
	In September 2013, the Company amended its non-cancellable operating lease for its office, laboratory, and warehouse space at its San Diego, California facility. The amendment extends the maturity date of the lease through July 31, 2020. As part of this amendment, the landlord waived the lease payments due from August 1, 2013 through December 31, 2013 of approximately $503,000, and the Company forfeited its long-term deposit of approximately $269,000. In conjunction with this amendment, the Company granted to the landlord a warrant to purchase common shares with a warrant coverage amount of $502,605. The warrant is exercisable for a five-year period beginning with the closing of the Company’s IPO on February 10, 2014, when such warrant became exercisable for 50,260 shares of common stock and the exercise price was fixed at $10.00 per share (see Notes 2, 5 and 10).
	The future minimum lease payments under the amended lease agreement as December 31, 2014 are as follows:
	2015	$	1,270,501
	2016		1,307,187
	2017		1,348,257
	2018		1,388,705
	2019		1,430,366
	Thereafter		855,136
	Total	$	7,600,152
	Employment Agreements
	Under the terms of certain employment agreements with executive officers, the Company incurred cash compensation expense of $150,000 immediately, and $225,000 annually, upon the closing of its IPO. All payments required under these agreements as a result of the closing of the Company’s IPO on February 10, 2014 were subsequently made in February and March 2014.
	Legal Proceedings
	In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.
	The Company’s former Vice President of Operations filed an administrative proceeding against the Company with the California Labor Commissioner in April 2013, seeking damages for alleged unpaid wages and penalties. A hearing was held on August 19, 2013 which resulted in a finding against the Company for approximately $65,000, of which $40,000 was paid during the year ended December 31, 2013 and $25,000 was accrued as of December 31, 2013. On February 25, 2014, the aforementioned administrative proceeding was settled in full following payment of the remaining $25,000 due.

Selected_Quarterly_Financial_D

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	20. Selected Quarterly Financial Data (Unaudited)
	The following is selected quarterly financial data as of and for the periods ending:
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	December 31, 2013
	Balance sheet data:
	Cash & cash equivalents		$	17,964		$	4,483		$	302,908		$	69,178
	Total assets			1,095,023			991,576			1,083,089			1,329,719
	Total non-current liabilities			1,252,921			508,527			167,291			462,001
	Total shareholders’ equity/(deficit)			(29,300,361	)		(8,215,261	)		(10,272,840	)		(12,456,014	)
	Statement of operations and comprehensive loss data:
	Revenues		$	35,154		$	48,369		$	31,922		$	18,800
	Gross profit/(loss)			(512,097	)		(544,868	)		(587,158	)		(551,532	)
	Research and development expenses			710,206			690,582			975,104			710,845
	General and administrative expenses			451,157			478,163			806,872			776,944
	Sales and marketing expenses			96,404			27,932			5,342			19,225
	Loss from operations			(1,769,864	)		(1,741,545	)		(2,374,476	)		(2,058,546	)
	Net loss		$	(1,925,974	)	$	(1,975,009	)	$	(2,860,191	)	$	(2,472,009	)
	Net loss per common share:1
	Basic		$	(10.67	)	$	(10.83	)	$	(15.72	)	$	(13.57	)
	Diluted		$	(10.67	)	$	(10.83	)	$	(15.72	)	$	(13.57	)
	Weighted-average shares outstanding used in computing net loss per share attributable
	to common shareholders:
	Basic			180,540			182,304			181,954			182,203
	Diluted			180,540			182,304			181,954			182,203
	1	Basic and diluted net loss per common share are computed independently for each of the components and quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	December 31, 2014
	Balance sheet data:
	Cash & cash equivalents		$	10,417,277		$	12,460,565		$	8,819,872		$	5,364,582
	Total assets			11,289,508			13,359,982			9,875,039			6,588,247
	Total non-current liabilities			473,080			5,203,742			5,339,618			5,378,033
	Total shareholders’ equity/(deficit)			9,356,778			6,883,269			3,344,897			(220,569	)
	Statement of operations and comprehensive loss data:
	Revenues		$	28,275		$	19,245		$	10,274		$	75,621
	Gross profit/(loss)			(630,040	)		(340,119	)		(527,907	)		(539,067	)
	Research and development expenses			1,008,929			1,107,678			1,310,905			1,070,278
	General and administrative expenses			1,876,912			1,032,855			1,060,812			1,231,418
	Sales and marketing expenses			11,142			423,361			812,005			890,496
	Loss from operations			(3,527,023	)		(2,904,013	)		(3,711,629	)		(3,731,259	)
	Net loss		$	(5,127,871	)	$	(2,996,840	)	$	(3,859,794	)	$	(3,881,541	)
	Net loss per common share:1
	Basic		$	(1.96	)	$	(0.67	)	$	(0.87	)	$	(0.87	)
	Diluted		$	(1.96	)	$	(0.67	)	$	(0.87	)	$	(0.87	)
	Weighted-average shares outstanding used in computing net loss per share attributable
	to common shareholders:
	Basic			2,617,275			4,449,603			4,449,603			4,449,603
	Diluted			2,617,275			4,449,603			4,449,603			4,449,603
	1	Basic and diluted net loss per common share are computed independently for each of the components and quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events
	Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. All of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for total proceeds of $177,500. All warrants sold in this offering have a per share exercise price of $1.56, are exercisable immediately and expire five years from the date of issuance. The closing of the sale of these securities to the underwriters occurred on February 13, 2015, when the Company received, after deducting underwriting discounts and additional costs paid to the underwriters, approximately $9.1 million of net cash proceeds. The total increase in capital as a result of the sale of these shares and warrants is expected to be approximately $8.9 million after deducting an estimated $0.2 million of additional non-underwriter costs incurred. Additionally, the underwriters were granted a 45-day option to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any. Subsequent to the closing of our second public offering on February 13, 2015, additional cash proceeds of approximately $6.7 million were received from the exercise of warrants sold in such offering.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
The Company and Business Activities	1. The Company and Business Activities
	Biocept, Inc. (“the Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor.
	The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures CEE microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic tests in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The tests the Company offers are classified as laboratory developed tests (LDTs), under the CLIA regulations.
	In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Basis of Presentation	Basis of Presentation
	The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America.
Use of Estimates	Use of Estimates
	The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates these estimates and judgments, including those related to inventories, long-lived assets, convertible debt, derivative liabilities, income taxes, and stock-based compensation. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
Reverse Stock Split and Change in Par Value of Common Stock and Preferred Stock	Reverse Stock Split and Change in Par Value of Common Stock and Preferred Stock
	In July 2013, in conjunction with its reincorporation in the state of Delaware, the Company initiated par values for preferred and common shares equal to $0.0001. In November 2013, the Company effected a 1:14 reverse stock split for all common shares. All references to share and per share amounts in the financial statements and accompanying notes to the financial statements have been retroactively restated to reflect the 1:14 reverse stock split and the change in par value.
Revenue Recognition	Revenue Recognition
	Revenue is recognized in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, Revenue Recognition, and ASC 954-605 Health Care Entities, Revenue Recognition which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred and title and the risks and rewards of ownership have been transferred to the client or services have been rendered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. For contract partners, revenue is recorded based upon the contractually agreed upon fee schedule. When assessing collectability, the Company considers whether there is sufficient payment history to reliably estimate a payor’s individual payment patterns. For new tests where there is limited evidence of payment history at the time the tests are completed, the Company recognizes revenue equal to the amount of cash received until such time as reimbursement experience can be established.
	The Company’s main source of revenue for the year ended December 31, 2013, and a significant source of revenue for the year ended December 31, 2014, is through contracted partners. This revenue is derived from clinical laboratory testing performed in the Company’s laboratories under agreements with such partners. As there is a contractually agreed upon price, and collectability from the partners is reasonably assured, revenues for these tests are recognized at the time the test is completed.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company places its cash and cash equivalents with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC). At times, deposits held may exceed the amount of insurance provided by the FDIC. The Company has not experienced any losses in its cash and cash equivalents and believes they are not exposed to any significant credit risk.
Fair Value Measurement	Fair Value Measurement
	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate their estimated fair values due to the short-term maturities of these financial instruments. See Note 5 for further details about the inputs and assumptions used to determine fair value measurements.
Concentration of Risk	Concentration of Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of temporary cash investments. The Company has not experienced losses in such accounts. Management believes that the Company is not exposed to any significant credit risk with respect to its cash and cash equivalents.
	In 2012, the Company launched commercial operations in partnership with a commercial partner, Clarient Diagnostic Services, Inc. (“Clarient”), a GE Healthcare Company. During the years ended December 31, 2013, the final year of this partnership, and December 31, 2014, when subsequent cash collections were made, 10% and 6%, respectively, of the revenues earned were billed through this relationship.
	In 2013, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, Dana-Farber Partners Cancer Care, Inc. (“Dana-Farber”). For the years ended December 31, 2013 and 2014, 77% and 32%, respectively, of the revenues earned were billed through this relationship. In addition, 100% and 72% of the receivables were due from Dana-Farber at December 31, 2013 and 2014, respectively.
	In 2014, the Company entered into a research support agreement with a not-for-profit tax-exempt organization, The University of Texas MD Anderson Cancer Center (“MD Anderson”). For the year ended December 31, 2014, 2% of the revenues earned were billed through this relationship. In addition, 28% of the receivables were due from MD Anderson at December 31, 2014.
	Concentrations of credit risk with respect to revenues and accounts receivable are primarily limited to certain clients including Clarient, Dana-Farber, and MD Anderson, and geographies to which the Company provides a significant volume of its services, and to specific payers of our services such as Medicare and individual insurance companies. The Company’s client base consists of a large number of geographically dispersed clients diversified across various customer types. For the year ended December 31, 2013, revenues derived from clients within the states of Massachusetts, California, and Texas accounted for approximately 77%, 22% and 1%, respectively, of total revenues.  For the year ended December 31, 2014, revenues derived from clients within the states of Massachusetts, California, and Texas accounted for approximately 32%, 15% and 34%, respectively, of total revenues.
	All of the Company’s sales for all periods presented were generated in the United States of America.
	Certain components used in the Company’s current or planned products are available from only one supplier, and substitutes for these components cannot be obtained easily or would require substantial design or manufacturing modifications or identification and qualification of alternative sources.
Accounts Receivable	Accounts Receivable
	Accounts receivable are carried at original invoice amounts, less an estimate for doubtful receivables, based on a review of all outstanding amounts on a periodic basis. The estimate for doubtful receivables is determined from an analysis of the accounts receivable on a quarterly basis, and is recorded as bad debt expense. As the Company only recognizes revenue to the extent collection is expected and reasonably assured, bad debt expense related to receivables from patient service revenue is recorded in general and administrative expense in the statement of operations and comprehensive loss. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received. As of December 31, 2013 and 2014, management determined that all of the amounts recorded as accounts receivable were collectible, and no allowance for doubtful accounts was needed.
Inventories	Inventories
	Inventories are valued at the lower of cost or market value. Cost is determined by the average cost method. The Company records adjustments to its inventory for estimated obsolescence or diminution in market value equal to the difference between the cost of the inventory and the estimated market value. At the point of loss recognition, a new cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Fixed Assets	Fixed Assets
	Fixed assets consist of machinery and equipment, furniture and fixtures, computer equipment and software, leasehold improvements, capital leased equipment and construction in process. Fixed assets are stated at cost less accumulated depreciation and amortization. Additions, improvements, and major renewals are capitalized. Maintenance, repairs, and minor renewals are expensed as incurred. Depreciation is determined using the straight-line method over the estimated useful lives of the assets, which range from three to five years. Leasehold improvements are amortized over the life of the lease or the asset, whichever is shorter. Depreciation expense for the years ended December 31, 2013 and 2014 was approximately $267,000 and $251,000, respectively.
	Upon sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation or amortization with any gain or loss recorded to the statement of operations.
	Fixed assets are reviewed for impairment whenever changes in circumstances indicate that the carrying amount of an asset may not be recoverable. These computations utilize judgments and assumptions inherent in the estimates of future cash flows to determine recoverability of these assets. If the assumptions about these assets were to change as a result of events or circumstances, the Company may be required to record an impairment loss.
Warrant Liability	Warrant Liability
	Warrants for shares that are contingently redeemable and for which the exercise price is not fixed are classified as liabilities on the accompanying balance sheets and carried at their estimated fair value, determined through use of a Black-Scholes valuation model. As of and for the years ended December 31, 2013 and 2014, the Company evaluated and concluded that the fair value obtained from the Black-Scholes method of valuing the warrant liability does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. At the end of each reporting period, any changes in fair value are recorded as a component of other income (expense). As of the closing of the Company’s IPO on February 10, 2014, the exercise price underlying the majority of the Company’s outstanding warrants was fixed and the fair value of those warrants was reclassified to shareholders’ deficit, while a preferred stock warrant to purchase an equivalent of 1,587 shares of common stock remains liability-classified at December 31, 2014.
Stock-based Compensation	Stock-based Compensation
	The Company accounts for stock-based compensation under the provisions of FASB ASC Topic 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock option awards on the date of grant using the Black-Scholes option pricing model (“Black-Scholes valuation model”), while the fair value of restricted stock unit awards is determined by the Company’s stock price on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company estimates forfeitures at the time of grant and revises these estimates in subsequent periods if actual forfeitures differ from those estimates. See additional information in Note 13.
	The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of equity instruments issued to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. These awards are recorded in expense and additional paid-in capital in shareholders’ equity over the applicable service periods based on the fair value of the options at the end of each period.
	Calculating the fair value of stock-based awards requires the input of highly subjective assumptions into the Black-Scholes valuation model. Stock-based compensation expense is calculated using the Company’s best estimates, which involves inherent uncertainties, and the application of management’s judgment. Significant estimates include the fair value of the Company’s common stock at the date of grant for awards granted prior to its IPO, the expected life of the stock option, stock price volatility, risk-free interest rate and forfeiture rate.
Research and Development	Research and Development
	Research and development costs are expensed as incurred. The amounts expensed in the years ended December 31, 2013 and 2014 were approximately $3,087,000 and $4,498,000, respectively, which includes salaries of research and development personnel.
Income Taxes	Income Taxes
	The Company provides for income taxes utilizing the liability method. Under the liability method, current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is computed for the expected future impact of differences between the financial reporting and tax bases of assets and liabilities and for the expected future tax benefit to be derived from tax credits. Tax rate changes are reflected in the computation of the income tax provision during the period such changes are enacted.
	Deferred tax assets are reduced by a valuation allowance when, in management’s opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company’s valuation allowance is based on available evidence, including its current year operating loss, evaluation of positive and negative evidence with respect to certain specific deferred tax assets including evaluation sources of future taxable income to support the realization of the deferred tax assets. The Company has established a full valuation allowance on the deferred tax assets as of December 31, 2013 and 2014, and therefore has not recognized any income tax benefit or expense in the periods presented.
	ASC 740, Income Taxes (“ASC 740”), clarifies the accounting for uncertainty in income taxes recognized in the financial statements. ASC 740 provides that a tax benefit from uncertain tax positions may be recognized when it is more-likely-than-not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. ASC 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
	The Company recognizes interest and/or penalties related to income tax matters in income tax expense. There is no accrual for interest or penalties for income taxes on the balance sheets at December 31, 2013 and 2014, and the Company has not recognized interest and/or penalties in the statements of operations for the years ended December 31, 2013 and 2014.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance that requires netting unrecognized tax benefits against deferred tax assets for a loss or other carryforward that would apply in settlement of uncertain tax positions. This guidance is effective for annual reporting periods beginning after December 15, 2013, and was effective for the Company’s fiscal year beginning January 1, 2014. The adoption of this guidance did not have a material impact on the Company’s financial statements or disclosures.
	In May 2014, the FASB issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
	In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.
	In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures.
	In November 2014, the FASB issued authoritative guidance requiring entities to consider all of a hybrid instrument’s stated and implied substantive terms and features, including any embedded derivative features being evaluated for bifurcation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. Early adoption is permitted. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures.

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Assumptions Used for Determining Fair Values of Common Stock Warrants	As of December 31, 2013, the aggregate common stock warrant liability of approximately $2,132,000 was estimated using a probability weighted Black-Scholes valuation model with the following assumptions for both the five-year and two-year common stock warrant terms separately:
		Five-year term			Two-year term
	Stock price	$  1.48 – 7.69			$  1.48 – 7.69
	Exercise price	$  1.48 – 7.69			$  1.48 – 7.69
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.73	%		0.38	%
	Expected life (in years)		5			2
	Expected volatility		100	%		90	%
	As of closing of the Company’s IPO on February 10, 2014, the aggregate common stock warrant liability of approximately $2,476,000 was estimated using a Black-Scholes valuation model with the following assumptions for both the five-year and two-year common stock warrant terms separately:
		Five-year term			Two-year term
	Stock price	$	8.91		$	8.91
	Exercise price	$	10		$	10
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		1.48	%		0.32	%
	Expected life (in years)		5			2
	Expected volatility		90	%		90	%
Schedule of Fair Value of Common and Preferred Stock Warrant Liability	The fair value attributed to the common and preferred share warrants as of December 31, 2013 and 2014 is as follows:
		Fair Value Measurements Using
		Quoted Prices			Significant
		in Active			Other			Significant
		Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)
	Liabilities
	Warrant Liability at December 31, 2013		—			—			2,140,532
	Warrant Liability at December 31, 2014		—			—			1,070
Summary of Changes in Fair Value of Common and Preferred Stock Warrants	The following table includes a summary of changes in the fair value of the common and preferred share warrants for the years ended December 31, 2013 and 2014:
		Fair Value Measurements
		at Reporting Date Using
		Significant Unobservable
		Inputs (Level 3)
	Balance at December 31, 2012	$	981,747
	Warrant liability incurred in 2013		2,322,042
	Change in fair value included in expense in 2013		(782,112	)
	Warrant liability reclassified to additional paid-in capital in 2013		(381,145	)
	Balance at December 31, 2013		2,140,532
	Warrant liability incurred in 2014		135,222
	Change in fair value included in expense in 2014		200,936
	Warrant liability reclassified to additional paid-in capital in 2014		(2,475,620	)
	Balance at December 31, 2014	$	1,070
Stock Option and Common Stock Warrants [Member]
Assumptions Used for Determining Fair Values of Stock Option and Common Stock Warrants	The fair values of these stock option and common stock warrants were estimated using Black-Scholes valuation models with the following assumptions:
		Options			Warrants
	Stock price	$	8.91		$	8.91
	Exercise price	$	9.3		$	12.5
	Expected dividend yield		0	%		0	%
	Discount rate-bond equivalent yield		0.07	%		1.46	%
	Expected life (in years)		0.12			5
	Expected volatility		70	%		90	%
Common Stock Warrants [Member]
Assumptions Used for Determining Fair Values of Stock Option and Common Stock Warrants	The fair value of this warrant was estimated using a Black-Scholes valuation model with the following assumptions:
	Stock price	$	4.74
	Exercise price	$	4.72
	Expected dividend yield		0	%
	Discount rate-bond equivalent yield		2.67	%
	Expected life (in years)		10
	Expected volatility		110	%

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details:
		December 31,		December 31,
		2013		2014
	Fixed Assets
	Machinery and equipment	$	2,761,560	$	2,922,303
	Furniture and office equipment		209,844		209,844
	Computer equipment and software		681,508		681,508
	Leasehold improvements		373,653		506,328
	Financed equipment		677,000		878,447
	Construction in process		12,299		72,172
			4,715,864		5,270,602
	Less accumulated depreciation and amortization		4,356,977		4,608,180
	Total fixed assets, net	$	358,887	$	662,422
	Accrued Liabilities
	Accrued interest	$	524,885	$	33,125
	Accrued payroll		125,299		82,241
	Deferred wages		1,377,987		—
	Accrued vacation		213,601		276,574
	Accrued bonuses		—		302,763
	Other		286		4,130
	Total accrued liabilities	$	2,242,058	$	698,833

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Summary of Short-term and Long-term Debt Obligations	The following is a summary of the Company’s short-term and long-term debt obligations:
		December 31,
		2013			2014
	Secured convertible note to a major shareholder. As of February 10, 2014, the secured convertible note was converted into common shares. (“2008 Convertible Note”) (See Note 10)	$	1,400,000		$	—
	Unsecured convertible notes, issued under a note and warrant purchase agreement dated as of June 28, 2013, net of discounts related to warrants aggregating $874,158 and $0 at December 31, 2013 and 2014, respectively. Includes notes of $2,505,000 and $0 to a major shareholder at December 31, 2013 and 2014, respectively. As of February 10, 2014, the unsecured convertible notes were converted into common shares. (“2013 Convertible Bridge Notes”) (See Note 10)		4,115,842			—
	Secured term loan agreement, net of discounts related to warrants and lender fees aggregating $0 and $245,484 at December 31, 2013 and 2014, respectively. ("April 2014 Credit Facility") (see Note 7)		—			4,754,516
	Other debt discount. As of February 10, 2014, the remaining unamortized portion of the other debt discount was reclassified to interest expense. (See Notes 8 and 10)		(315,243	)		—
	Total notes payable		5,200,599			4,754,516
	Less current portion		5,200,599			—
	Long-term portion	$	—		$	4,754,516

Accounting_for_StockBased_Comp1

Accounting for Stock-Based Compensation Expense (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The assumptions used in the Black-Scholes pricing model for options granted during the years ended December 31, 2013 and 2014 are as follows:
			2013				2014
	Stock and exercise prices		$	5.18			$2.79 - $9.11
	Expected dividend yield			0.00%				0.00%
	Discount rate-bond equivalent yield		1.38% – 1.69%				1.56% – 2.06%
	Expected life (in years)		5.26 – 6.02				5.00 – 6.08
	Expected volatility			105.00%			90.0% – 100.0%
	Expected forfeiture rate		0.00% – 5.00%				0.00% – 5.00%
Summary of Stock Option Activity for Option Awards Granted	A summary of stock option activity for 2013 and 2014 is as follows:
											Average
							Weighted				Remaining
			Number of				Average Exercise				Contractual
			Shares				Price Per Share				Term in Years
	Outstanding at December 31, 2012			63,518			$	4.97				6.2
	Granted			300,438			$	5.18
	Exercised			(4,021	)		$	5
	Cancelled/forfeited/expired			(26,829	)		$	5.2
	Outstanding at December 31, 2013			333,106			$	5.14				9.3
	Granted			647,298			$	6.71
	Exercised			—				—
	Cancelled/forfeited/expired			(74,210	)		$	4.77
	Outstanding at December 31, 2014			906,194			$	6.29				9
	Vested and unvested expected to vest, December 31, 2014			901,882			$	6.28				8.9
Schedule of Information about Options Outstanding and Exercisable	Further information about the options outstanding and exercisable is as follows:
	Options Outstanding and Exercisable at December 31, 2013
									Weighted
	Weighted								Average
	Average				Total Shares				Contractual				Total Shares
	Exercise Price				Outstanding				Life (in years)				Exercisable
	$	4.62				20,208				7.3				13,731
	$	5.04				12,460				5.5				12,455
	$	5.18				300,438				9.6				110,825
						333,106								137,011
	Options Outstanding and Exercisable at December 31, 2014
									Weighted
	Weighted								Average
	Average				Total Shares				Contractual				Total Shares
	Exercise Price				Outstanding				Life (in years)				Exercisable
	$	2.79				52,500				9.8				—
	$	4.42				103,934				8.8				29,715
	$	5.22				413,962				8.8				241,918
	$	7.5				43,000				9.2				—
	$	8.88				238,500				9.1				—
	$	9.11				54,298				9.1				54,298
						906,194								325,931
Schedule of Performance Stock Units Vesting Percentage	Vesting of these RSUs may occur based on the Company’s achievement of specified objectives as determined by the Company’s Board of Directors or Compensation Committee, as follows:
			Percentage of
			Overall RSU
			Grant Subject to
			Vesting
	Target
	Minimum revenue in 2015			25	%
	Maximum EBITDA loss in 2015			15	%
	Attainment of financial plan for fiscal 2015			20	%
	Minimum value of strategic agreements by December 31, 2015			20	%
	Implementation of four new diagnostic test panels by December 31, 2015			20	%
	Total			100	%
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the statement of operations during the periods presented:
			Years Ended December 31,
			2013				2014
	Stock Options
	Cost of revenues		$	-			$	20,961
	Research and development expenses			298,618				163,229
	General and administrative expenses			221,726				1,139,309
	Sales and marketing expenses			—				76,204
	Total expenses related to stock options			520,344				1,399,703
	RSUs
	Research and development expenses			72,500				30,000
	General and administrative expenses			359,677				392,958
	Total stock-based compensation		$	952,521			$	1,822,661

Net_Loss_per_Common_Share_Tabl

Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:
		For the year ended
		December 31,
		2013		2014
	Series A preferred (number of common stock equivalents)		1,652,851		—
	Preferred warrants outstanding (number of common stock equivalents)		192,262		1,587
	Preferred share RSUs (number of common stock equivalents)		89,647		73,151
	Common warrants outstanding		836,890		609,187
	Notes payable convertible into common shares		1,110,649		—
	Common share RSUs		133,971		178,467
	Common options outstanding		333,106		906,194
	Total anti-dilutive common share equivalents		4,349,376		1,768,586

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	For the year ended December 31, 2013 and 2014, the provision for income taxes was calculated as follows:
		For the year ended December 31,
		2013			2014
	Current:
	Federal	$	—		$	—
	State		800			1,506
	Total		800			1,506
	Deferred
	Federal		—			—
	State		—			—
	Total		—			—
	Provision for income tax	$	800		$	1,506
Reconciliation of Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes	The following table provides a reconciliation between income taxes computed at the federal statutory rate and the Company’s provision for income taxes:
		For the year ended December 31,
		2013			2014
	Income tax at statutory rate	$	(3,139,368	)	$	(5,393,944	)
	State liability		(321,058	)		(813,039	)
	Permanent items		6,932			14,374
	Stock Compensation		171,003			159,128
	Nondeductible Interest		395,089			399,249
	Expiration of net operating losses		188,316			1,136,317
	Other		(6,723	)		339,636
	Research and development credit		(103,500	)		(127,491	)
	Valuation allowance		2,810,109			4,287,276
	Provision for income tax	$	800		$	1,506
Summary of Deferred Tax Assets	The tax effects of carryforwards that give rise to deferred tax assets consist of the following:
		For the year ended December 31,
		2013			2014
	Net operating loss carryforward	$	43,666,636		$	47,329,815
	Research and development credits		5,114,652			5,242,144
	Accruals and other		742,045			1,216,600
	Deferred rent		176,893			198,945
			49,700,226			53,987,504
	Less valuation allowance		(49,700,226	)		(53,987,504	)
	Net deferred tax assets	$	—		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	The future minimum lease payments under the amended lease agreement as December 31, 2014 are as follows:
	2015	$	1,270,501
	2016		1,307,187
	2017		1,348,257
	2018		1,388,705
	2019		1,430,366
	Thereafter		855,136
	Total	$	7,600,152

Selected_Quarterly_Financial_D1

Selected Quarterly Financial Data (Unaudited) (Table)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary of Selected Quarterly Financial Data	The following is selected quarterly financial data as of and for the periods ending:
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	December 31, 2013
	Balance sheet data:
	Cash & cash equivalents		$	17,964		$	4,483		$	302,908		$	69,178
	Total assets			1,095,023			991,576			1,083,089			1,329,719
	Total non-current liabilities			1,252,921			508,527			167,291			462,001
	Total shareholders’ equity/(deficit)			(29,300,361	)		(8,215,261	)		(10,272,840	)		(12,456,014	)
	Statement of operations and comprehensive loss data:
	Revenues		$	35,154		$	48,369		$	31,922		$	18,800
	Gross profit/(loss)			(512,097	)		(544,868	)		(587,158	)		(551,532	)
	Research and development expenses			710,206			690,582			975,104			710,845
	General and administrative expenses			451,157			478,163			806,872			776,944
	Sales and marketing expenses			96,404			27,932			5,342			19,225
	Loss from operations			(1,769,864	)		(1,741,545	)		(2,374,476	)		(2,058,546	)
	Net loss		$	(1,925,974	)	$	(1,975,009	)	$	(2,860,191	)	$	(2,472,009	)
	Net loss per common share:1
	Basic		$	(10.67	)	$	(10.83	)	$	(15.72	)	$	(13.57	)
	Diluted		$	(10.67	)	$	(10.83	)	$	(15.72	)	$	(13.57	)
	Weighted-average shares outstanding used in computing net loss per share attributable
	to common shareholders:
	Basic			180,540			182,304			181,954			182,203
	Diluted			180,540			182,304			181,954			182,203
	1	Basic and diluted net loss per common share are computed independently for each of the components and quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.
			First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	December 31, 2014
	Balance sheet data:
	Cash & cash equivalents		$	10,417,277		$	12,460,565		$	8,819,872		$	5,364,582
	Total assets			11,289,508			13,359,982			9,875,039			6,588,247
	Total non-current liabilities			473,080			5,203,742			5,339,618			5,378,033
	Total shareholders’ equity/(deficit)			9,356,778			6,883,269			3,344,897			(220,569	)
	Statement of operations and comprehensive loss data:
	Revenues		$	28,275		$	19,245		$	10,274		$	75,621
	Gross profit/(loss)			(630,040	)		(340,119	)		(527,907	)		(539,067	)
	Research and development expenses			1,008,929			1,107,678			1,310,905			1,070,278
	General and administrative expenses			1,876,912			1,032,855			1,060,812			1,231,418
	Sales and marketing expenses			11,142			423,361			812,005			890,496
	Loss from operations			(3,527,023	)		(2,904,013	)		(3,711,629	)		(3,731,259	)
	Net loss		$	(5,127,871	)	$	(2,996,840	)	$	(3,859,794	)	$	(3,881,541	)
	Net loss per common share:1
	Basic		$	(1.96	)	$	(0.67	)	$	(0.87	)	$	(0.87	)
	Diluted		$	(1.96	)	$	(0.67	)	$	(0.87	)	$	(0.87	)
	Weighted-average shares outstanding used in computing net loss per share attributable
	to common shareholders:
	Basic			2,617,275			4,449,603			4,449,603			4,449,603
	Diluted			2,617,275			4,449,603			4,449,603			4,449,603
	1	Basic and diluted net loss per common share are computed independently for each of the components and quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.

Initial_Public_Offering_Additi

Initial Public Offering - Additional Information (Detail) (USD $)	0 Months Ended				12 Months Ended		0 Months Ended
	Feb. 10, 2014	Feb. 04, 2014	Jun. 28, 2013	Nov. 30, 2011	Dec. 31, 2014	Dec. 31, 2013	Feb. 13, 2014	Apr. 30, 2014	Jul. 22, 2013	Jul. 21, 2013
Class Of Stock [Line Items]
Initial public offering, number of shares issued		1,900,000
Initial public offering, price per share		$10
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs	$17,400,000				$17,390,240
Increase in capital shares value	16,500,000				16,458,104
Additional costs incurred prior to, and associated with IPO, beginning of period	900,000				932,136
Purchase of common stock by underwriters to cover overallotments, number of shares					285,000
Purchase of common stock by underwriters to cover overallotments, per share					$9.30
Exercise price of warrants	$10
Overallotment issued to underwriter to purchase common stock, period					45 days
Purchase of common stock by underwriters to cover overallotments, grant date fair value					202,143
Warrants to purchase common stock, period					5 years
Issuance of warrants to purchase shares of common stock, grant date fair value					544,116
Series A Preferred Stock, shares converted to common stock		69,421,047			69,421,047
Common stock, shares issued upon conversion of Series A Preferred Stock		1,652,851			1,652,851
Common stock, shares authorized		40,000,000			40,000,000	53,000,000			14,600,000
Preferred stock, shares authorized		5,000,000							100,000,000	14,600,000
Debt, principal amount converted	1,400,000		20,231,000		6,600,000	20,231,000
Conversion price of notes	$10				$10
Convertible Note converted into preferred/common stock	163,399
Shares of common stock vested as settlement of certain restricted stock units	73,151
Lock-up period	180 days
Preferred warrants outstanding after cancellation of warrants due to early termination clauses	1,587
Warrants reclassified to additional paid-in capital	2,475,620
Unamortized discounts related to warrants	996,024
Non-cash underwriter IPO costs	279,760				279,760
Non-cash underwriter IPO discounts	1,330,000
Offering costs associated with IPO	932,136
Maximum amount of line of credit					2,600,000
Line of credit, outstanding balance repaid	2,346,000				2,346,000
Line of credit, accrued interest paid	27,043
Stock options granted					647,298	300,438
Option awards vesting period				10 years
Additional cash compensation expense					150,000
Annual cash compensation expense					225,000
Repayment of laboratory equipment dues to supplier					70,000
Executive Officer [Member]
Class Of Stock [Line Items]
Payment of deferred salary obligations							1,009,552
Employee [Member]
Class Of Stock [Line Items]
Payment of deferred salary obligations							344,883
2013 Equity Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares authorized					403,571
Increase in number of shares of common stock covered by plan	800,000
Option awards vesting period							3 years
Option awards expiration period							10 years
2013 Equity Incentive Plan [Member] | Non-Employee Directors [Member]
Class Of Stock [Line Items]
Stock options granted							238,500
2013 Equity Incentive Plan [Member] | Employee Directors [Member]
Class Of Stock [Line Items]
Stock options granted							54,298
2013 Equity Incentive Plan [Member] | Non Executive Chairman [Member]
Class Of Stock [Line Items]
Stock options granted							53,108
Common Stock [Member]
Class Of Stock [Line Items]
Initial public offering, number of shares issued					1,900,000
Increase in capital shares value					190
Exercise price of warrants								$4.72
Warrants to purchase common stock, period								10 years
Series A Preferred Stock, shares converted to common stock					1,652,851
Convertible Note converted into preferred/common stock	433,883				163,399
2008 Convertible Note [Member]
Class Of Stock [Line Items]
Debt, principal amount converted	1,400,000				1,400,000
Conversion price of notes	$10
Convertible Note converted into preferred/common stock	163,399
2008 Convertible Note [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Convertible Note converted into preferred/common stock	163,399
2013 Convertible Bridge Notes [Member]
Class Of Stock [Line Items]
Exercise price of warrants	$10
Debt, principal amount converted	5,165,000				5,165,000
Accrued interest on convertible debt converted					313,017
Conversion price of notes	$10				$10
Convertible Note converted into preferred/common stock	547,794				548,803
Warrants reclassified to additional paid-in capital	258,249
Warrants reclassified to additional paid-in capital	1,562,968
2013 Convertible Bridge Notes [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Convertible Note converted into preferred/common stock	547,794
Line of Credit [Member]
Class Of Stock [Line Items]
Exercise price of warrants	$10
Warrants reclassified to additional paid-in capital	128,903
Collateral amount provided to secure Line of Credit	2,578,104
Convertible Bridge Notes And Line Of Credit [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$10
Warrants reclassified to additional paid-in capital	387,152				387,152
Warrants reclassified to additional paid-in capital					2,475,620
Accrued interest [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted	233,982		2,581,000			2,581,000
Accrued interest [Member] | 2008 Convertible Note [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted	233,982				233,982
Accrued interest [Member] | 2013 Convertible Bridge Notes [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted	$313,017
Aegis Capital Corp. [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock					95,000
Exercise price of warrants					$12.50

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	0 Months Ended	3 Months Ended								12 Months Ended		0 Months Ended
	Feb. 10, 2014	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 13, 2015	Dec. 31, 2012
Liquidity And Managements Plans [Line Items]
Accumulated deficit		($138,287,022)				($122,420,976)				($138,287,022)	($122,420,976)
Net loss		-3,881,541	-3,859,794	-2,996,840	-5,127,871	-2,472,009	-2,860,191	-1,975,009	-1,925,974	-15,866,046	-9,233,183
Cash and cash equivalents		5,364,582	8,819,872	12,460,565	10,417,277	69,178	302,908	4,483	17,964	5,364,582	69,178		185,256
Net proceeds from issuance of common stock	17,400,000									17,390,240
Subsequent Event [Member]
Liquidity And Managements Plans [Line Items]
Net proceeds from issuance of common stock												9,100,000
Proceeds from warrant exercises												6,700,000
Note Agreements with Certain Shareholders and Line of Credit [Member]
Liquidity And Managements Plans [Line Items]
Debt instrument carrying amount		500,000				6,200,000				500,000	6,200,000
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Debt instrument carrying amount		4,754,516								4,754,516
Credit facility, net		$5,000,000								$5,000,000

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	0 Months Ended	1 Months Ended	3 Months Ended								12 Months Ended
	Dec. 31, 2010	Nov. 30, 2013	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 10, 2014	Jul. 31, 2013	Jul. 30, 2013
Summary Of Significant Accounting Policies [Line Items]
Common stock, par value			$0.00				$0.00				$0.00	$0.00		$0.00	$0.00
Preferred stock, par value							$0.00					$0.00		$0.00
Reverse stock split of common shares, ratio	0.25	0.0714
Reverse stock split, description											In November 2013, the Company effected a 1:14 reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse split as if it had occurred on January 1, 2013.
Number of suppliers											one supplier
Allowance for doubtful accounts			$0				$0				$0	$0
Depreciation expense											251,000	267,000
Preferred warrants outstanding after cancellation of warrants due to early termination clauses													1,587
Research and development expenses			1,070,278	1,310,905	1,107,678	1,008,929	710,845	975,104	690,582	710,206	4,497,790	3,086,737
Accrual for interest or penalties for income taxes			0				0				0	0
Interest or penalties expense on income taxes											$0	$0
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets											3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets											5 years
Customer Concentration Risk [Member] | Sales Revenue [Member] | Massachusetts [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											32.00%	77.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | California [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											15.00%	22.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | Texas [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											34.00%	1.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | Clarient Diagnostic Services, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											6.00%	10.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | Dana Farber Partners Cancer Care, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											32.00%	77.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | MD Anderson Cancer Center [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											2.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Dana Farber Partners Cancer Care, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											72.00%	100.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | MD Anderson Cancer Center [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage											28.00%

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 10, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants				10
Warrant for preferred shares outstanding	1,587
Warrant liability	$1,070	$2,140,532
Change in fair value of warrant liability	-200,936	782,112	536,000
Overallotment issued to underwriter to purchase common stock, period	45 days
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000
Purchase of common stock by underwriters to cover overallotments, grant date fair value	202,143
Issuance of warrants to purchase shares of common stock, grant date fair value	544,116
Warrant term	5 years
April 2014 Credit Facility [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock, grant date fair value	233,107
Warrant issued to lender	52,966
Warrant term	10 years
Aegis Capital Corp. [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants	$12.50
Issuance of warrants to purchase shares of common stock	95,000
Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Exercise price of warrants				10
Warrant liability		2,132,000
Fair value assumption, probability rate		25.00%
Fair value price		0
Common Stock Warrants [Member] | IPO
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability				2,476,000
Common Stock Warrants [Member] | Black Scholes Valuation Model
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value assumption, probability rate		75.00%
Five-Year Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)	5 years	5 years
Five-Year Term [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)		5 years
Five-Year Term [Member] | Common Stock Warrants [Member] | IPO
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)				5 years
Two-Year Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)	2 years	2 years
Two-Year Term [Member] | Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)		2 years
Two-Year Term [Member] | Common Stock Warrants [Member] | IPO
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Expected life (in years)				2 years

Fair_Value_Measurement_Assumpt

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Five-Year Term [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price	$8.91
Exercise price	$10
Expected dividend yield	0.00%	0.00%
Discount rate-bond equivalent yield	1.48%	1.73%
Expected life (in years)	5 years	5 years
Expected volatility	90.00%	100.00%
Five-Year Term [Member] | Minimum [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price		1.48
Exercise price		1.48
Five-Year Term [Member] | Maximum [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price		7.69
Exercise price		7.69
Two-Year Term [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price	$8.91
Exercise price	$10
Expected dividend yield	0.00%	0.00%
Discount rate-bond equivalent yield	0.32%	0.38%
Expected life (in years)	2 years	2 years
Expected volatility	90.00%	90.00%
Two-Year Term [Member] | Minimum [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price		1.48
Exercise price		1.48
Two-Year Term [Member] | Maximum [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Stock price		7.69
Exercise price		7.69

Fair_Value_Measurement_Schedul

Fair Value Measurement - Schedule of Fair Value of Common and Preferred Stock Warrant Liability (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$1,070	$2,140,532
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$1,070	$2,140,532

Fair_Value_Measurement_Summary

Fair Value Measurement - Summary of Changes in Fair Value of Common and Preferred Stock Warrants (Detail) (Warrants [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$2,140,532	$981,747
Warrant liability incurred	135,222	2,322,042
Change in fair value included in expense	200,936	-782,112
Warrant liability reclassified to additional paid-in capital	-2,475,620	-381,145
Ending Balance	$1,070	$2,140,532

Fair_Value_Measurement_Assumpt1

Fair Value Measurement - Assumptions Used for Determining Fair Values of Stock Option and Common Stock Warrants (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Revolving Credit Facility
Fair Value Assumption Black Scholes Valuation Models [Line Items]
Stock price	$4.74
Exercise price	$4.72
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	2.67%
Expected life (in years)	10 years
Expected volatility	110.00%
Options [Member]
Fair Value Assumption Black Scholes Valuation Models [Line Items]
Stock price	$8.91
Exercise price	$9.30
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	0.07%
Expected life (in years)	1 month 13 days
Expected volatility	70.00%
Warrants [Member]
Fair Value Assumption Black Scholes Valuation Models [Line Items]
Stock price	$8.91
Exercise price	$12.50
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.46%
Expected life (in years)	5 years
Expected volatility	90.00%

Balance_Sheet_Details_Schedule

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fixed Assets
Machinery and equipment	$2,922,303	$2,761,560
Furniture and office equipment	209,844	209,844
Computer equipment and software	681,508	681,508
Leasehold improvements	506,328	373,653
Financed equipment	878,447	677,000
Construction in process	72,172	12,299
Total fixed assets, gross	5,270,602	4,715,864
Less accumulated depreciation and amortization	4,608,180	4,356,977
Total fixed assets, net	662,422	358,887
Accrued Liabilities
Accrued interest	33,125	524,885
Accrued payroll	82,241	125,299
Deferred wages		1,377,987
Accrued vacation	276,574	213,601
Accrued bonuses	302,763
Other	4,130	286
Total accrued liabilities	$698,833	$2,242,058

Balance_Sheet_Details_Addition

Balance Sheet Details - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cost related to IPO Issuance [Abstract]
Cost related to IPO issuance	$63,111	$538,318
Liability for associated unpaid invoices	63,111	328,221
Additional stock issuance cost offset against paid-in capital	1,211,896
Non-cash discount	1,330,000
Stock option and restricted stock offset against paid-in capital	$746,259

April_2014_Credit_Facility_Add

April 2014 Credit Facility - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2014	Feb. 10, 2014
Line of Credit Facility [Line Items]
Maximum amount of line of credit	$2,600,000
Exercise price of warrants				$10
Warrant term	5 years
Other non-current assets, net	23,194	500
Issuance of warrants to purchase shares of common stock, grant date fair value	544,116
Total amount of interest expense recorded	1,789,680	2,070,064
Unamortized discount				996,024
UBS Bank [Member] | One Year [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage			3.00%
UBS Bank [Member] | Two Years [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage			2.00%
UBS Bank [Member] | Three Years [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage			1.00%
UBS Bank [Member] | Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period			7.95%
UBS Bank [Member] | Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period			7.71%
UBS Bank [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan			4,927,000
Credit facility fee due			50,000
Line of Credit Facility, Interest Rate During Period			7.95%
Percentage of final interest payment due at maturity			5.50%
Issuance costs	73,104
Net proceeds from credit facility	4,926,896
Other non-current assets, net	28,932
Issuance of warrants to purchase shares of common stock, grant date fair value	233,107
Total amount of interest expense recorded	380,264
Unamortized discount	245,000
Accretion of discount recognized as interest expense	61,000
Effective annual interest rate	10.81%		10.81%
UBS Bank [Member] | Second Term Loan [Member]
Line of Credit Facility [Line Items]
Maximum amount of line of credit			5,000,000
Debt Instrument covenant requirement revenue			9,000,000
Line Of Credit Facility Fees Amount Payable			50,000
Percentage of final interest payment due at maturity			5.50%
Common Stock [Member]
Line of Credit Facility [Line Items]
Exercise price of warrants			4.72
Warrant issued to lender			52,966
Warrant term			10 years
Minimum [Member] | UBS Bank [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount			250,000

Line_of_Credit_Additional_Info

Line of Credit - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Feb. 10, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 31, 2013
		RelatedParty
Line Of Credit [Line Items]
Maximum amount of line of credit		$2,600,000
Number of related parties guaranteed the loan and pledged financial assets to the bank		5
Line of credit, outstanding balance repaid	2,346,000	2,346,000
Line of credit, accrued interest paid	27,043
Exercise price of warrants	$10
Reclassification of warrant liability derivative due to triggering event	513,603	2,475,620	381,145
U B S Bank | Line of Credit [Member]
Line Of Credit [Line Items]
Credit facility, net			2,000,000	1,500,000
Maximum amount of line of credit		2,600,000
Common stock warrants coverage amount of the fair market value		50.00%
Debt instrument, description of variable rate basis		Interest accrued daily on the outstanding balance and was paid monthly at a variable rate which, as of December 31, 2013, was 2.75% over the 30 day LIBOR rate or a nominal annual interest rate of 2.92%.
Collateral amount provided to secure Line of Credit	$2,578,104
Exercise price of warrants	$10
Warrants reclassified to additional paid-in capital	128,903
U B S Bank | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line Of Credit [Line Items]
Debt instrument, basis spread on variable rate			2.75%
U B S Bank | Line of Credit [Member] | Base Rate [Member]
Line Of Credit [Line Items]
Debt instrument, basis spread on variable rate			2.92%

Notes_Payable_Summary_of_Short

Notes Payable - Summary of Short-term and Long-term Debt Obligations (Detail) (USD $)	Dec. 31, 2014	Feb. 10, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Debt Instrument unamortized discount		($996,024)
Total notes payable	4,754,516		5,200,599
Less current portion			5,200,599
Long-term portion	4,754,516
2008 Convertible Note [Member]
Debt Instrument [Line Items]
Debt instrument carrying amount			1,400,000
2013 Convertible Bridge Notes [Member]
Debt Instrument [Line Items]
Debt instrument carrying amount			4,115,842
Debt Instrument unamortized discount	0		-874,158
Other Debt
Debt Instrument [Line Items]
Debt Instrument unamortized discount			-315,243
April 2014 Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument carrying amount	4,754,516
Debt Instrument unamortized discount	($245,484)		$0

Notes_Payable_Summary_of_Short1

Notes Payable - Summary of Short-term and Long-term Debt Obligations (Parenthetical) (Detail) (USD $)	Feb. 10, 2014	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Unamortized discount	$996,024
April 2014 Credit Facility [Member]
Debt Instrument [Line Items]
Unamortized discount		245,484	0
Note payable, gross		4,754,516
2013 Convertible Bridge Notes [Member]
Debt Instrument [Line Items]
Unamortized discount		0	874,158
Note payable, gross			4,115,842
Major Shareholder [Member]
Debt Instrument [Line Items]
Note payable, gross			3,905,000
Major Shareholder [Member] | 2013 Convertible Bridge Notes [Member]
Debt Instrument [Line Items]
Note payable, gross		$0	$2,505,000

Note_Payable_Additional_Inform

Note Payable - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Debt, principal amount converted	$1,400,000	$20,231,000	$6,600,000	$20,231,000
Convertible Note converted into preferred/common stock	163,399
Conversion price of notes	$10		$10
Warrants reclassified to additional paid-in capital	2,475,620
Exercise price of warrants	$10
Interest Payable current and non-current portion			88,000	516,000
Notes Payable [Member]
Debt Instrument [Line Items]
Total interest expense on debt			1,768,000	1,964,000
2008 Convertible Note [Member]
Debt Instrument [Line Items]
Debt, principal amount converted	1,400,000		1,400,000
Convertible Note converted into preferred/common stock	163,399
Conversion price of notes	$10
2013 Convertible Bridge Notes [Member]
Debt Instrument [Line Items]
Debt, principal amount converted	5,165,000		5,165,000
Accrued interest on convertible debt converted			313,017
Convertible Note converted into preferred/common stock	547,794		548,803
Conversion price of notes	$10		$10
Warrants reclassified to additional paid-in capital	1,562,968
Warrants reclassified to additional paid-in capital	258,249
Exercise price of warrants	$10
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Convertible Note converted into preferred/common stock		42,245,834
Series A Convertible Preferred Stock [Member] | 2008 Convertible Note [Member]
Debt Instrument [Line Items]
Exercise price of warrants			$0.60
Accrued interest [Member]
Debt Instrument [Line Items]
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Accrued interest [Member] | 2008 Convertible Note [Member]
Debt Instrument [Line Items]
Accrued interest on convertible debt converted	233,982		233,982
Accrued interest [Member] | 2013 Convertible Bridge Notes [Member]
Debt Instrument [Line Items]
Accrued interest on convertible debt converted	$313,017

Convertible_Notes_and_Warrants1

Convertible Notes and Warrants - Goodman Note - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

1 Months Ended

Feb. 10, 2014

Jun. 28, 2013

Dec. 31, 2014

Dec. 31, 2013

31-May-10

Jul. 31, 2013

Jan. 31, 2009

Apr. 30, 2014

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Feb. 28, 2009

Apr. 30, 2005

Debt Conversion [Line Items]

Exercise price of warrants

$10

Debt, principal amount converted

$1,400,000

$20,231,000

$6,600,000

$20,231,000

Convertible Note converted into preferred/common stock

163,399

Conversion price of notes

$10

$10

Warrant liability

1,070

2,140,532

Period for which warrants will be exercisable beginning with the closing of IPO

5 years

Aegis Capital Corp. [Member]

Debt Conversion [Line Items]

Exercise price of warrants

$12.50

Common Stock [Member]

Debt Conversion [Line Items]

Exercise price of warrants

$4.72

Convertible Note converted into preferred/common stock

433,883

163,399

Common Stock [Member] | Aegis Capital Corp. [Member]

Debt Conversion [Line Items]

Reclassification of common stock warrant liability to APIC upon IPO.

95,000

Accrued interest [Member]

Debt Conversion [Line Items]

Accrued interest on convertible debt converted

233,982

2,581,000

2,581,000

Series A Convertible Preferred Stock [Member]

Debt Conversion [Line Items]

Convertible Note converted into preferred/common stock

42,245,834

Goodman Note [Member]

Debt Conversion [Line Items]

Debt, fixed interest rate per annum

3.25%

Principal payment, beginning date

1-May-10

Repayment of notes payable

750,000

Additional principal payment

0

0

180,000

135,000

Debt, principal amount converted

1,935,000

Conversion price of notes

$0.54

Shares of preferred stock converted into shares of common stock

89,936

Goodman Note [Member] | Common Stock [Member]

Debt Conversion [Line Items]

Exercise price of warrants

$10

Warrants reclassified to additional paid-in capital

23,809

Warrant liability

62,000

Period for which warrants will be exercisable beginning with the closing of IPO

2 years

Goodman Note [Member] | Accrued interest [Member]

Debt Conversion [Line Items]

Accrued interest on convertible debt converted

105,000

Goodman Note [Member] | Series A Convertible Preferred Stock [Member]

Debt Conversion [Line Items]

Percentage of principal amount of convertible loan divided by the exercise price which equals number of shares exercised

10.00%

Notice period for early termination of warrant

20 days

Exercise price of warrants

$0.60

Convertible Note converted into preferred/common stock

3,777,324

Goodman Note [Member] | Minimum [Member] | Series A Convertible Preferred Stock [Member]

Debt Conversion [Line Items]

Proceeds from issuance of warrants for equity finance

2,000,000

May 1, 2010 through January 31, 2011 [Member] | Goodman Note [Member]

Debt Conversion [Line Items]

Periodic principal payment

45,000

February 1, 2012 through January 31, 2014 [Member] | Goodman Note [Member]

Debt Conversion [Line Items]

Periodic principal payment

90,000

February 1, 2014 through the maturity date [Member] | Goodman Note [Member]

Debt Conversion [Line Items]

Periodic principal payment

150,000

Unsecured Debt [Member] | Goodman Note [Member]

Debt Conversion [Line Items]

Debt instrument initial principal amount

3,000,000

$15,000,000

Percentage of arrear accrued interest payable due on each quarter beginning February 1, 2009

25.00%

Percentage of uncompounded accrued interest payable

75.00%

Unsecured Debt [Member] | Goodman Note [Member] | Prime Rate [Member]

Debt Conversion [Line Items]

Debt, spread on variable rate

0.25%

Unsecured Debt [Member] | Before Amendment | Goodman Note [Member]

Debt Conversion [Line Items]

Debt, maturity date description

The note required interest payments and principal settlement upon maturity at the earliest of (a) April 20, 2010, (b) the Company being acquired, or (c) the Company having a change in control, other than through the sale of preferred shares.

Unsecured Debt [Member] | After Amendment | Goodman Note [Member]

Debt Conversion [Line Items]

Debt, maturity date description

The principal and any interest amounts that remain outstanding was set to mature at the earlier of (a) April 20, 2010, or (b) the date immediately prior to the Companybs closing of an acquisition or asset transfer as defined by the Companybs amended and restated articles of incorporation.

Convertible_Notes_and_Warrants2

Convertible Notes and Warrants - 2008 Convertible Note - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2008
Temporary Equity [Line Items]
Exercise price of warrants	$10
Debt, principal amount converted	$1,400,000	$20,231,000	$6,600,000	$20,231,000
Conversion price of notes	$10		$10
Convertible Note converted into preferred/common stock	163,399
Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible Note converted into preferred/common stock		42,245,834
2008 Convertible Note [Member]
Temporary Equity [Line Items]
Debt instrument initial principal amount					1,400,000
Debt, maturity date description			The 2008 Convertible Note accrued interest at a variable rate based on prime per annum payable at maturity, and matured at the earliest occurrence of, (a) the passing of 48 months from inception of the note, (b) the closing date of an acquisition or asset transfer as defined by the note, or (c) the closing date of the issuance and sale of shares of common stock of the Company in the Companybs IPO.
Debt, principal amount converted	1,400,000		1,400,000
Conversion price of notes	$10
Convertible Note converted into preferred/common stock	163,399
2008 Convertible Note [Member] | Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	233,982		233,982
2008 Convertible Note [Member] | Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Proceeds received from sale of preferred shares including conversion of convertible loan amount that triggers conversion of debt			20,000,000
Proceeds sale of shares that triggers conversion of debt			2,000,000
Notice period of warrant conversion			20 days
Exercise price of warrants			$0.60
2008 Convertible Note [Member] | Series A Convertible Preferred Stock [Member] | Minimum [Member]
Temporary Equity [Line Items]
Proceeds from issuance of warrants for equity finance			$2,000,000

Convertible_Notes_and_Warrants3

Convertible Notes and Warrants - 2011 Convertible Bridge Notes - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2011	Dec. 31, 2011	Dec. 31, 2012	Feb. 11, 2011
Temporary Equity [Line Items]
Conversion price of notes	$10		$10
Warrant liability			$1,070	$2,140,532
Debt, principal amount converted	1,400,000	20,231,000	6,600,000	20,231,000
Shares issued upon conversion of debt	163,399
Exercise price of warrants	$10
Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Warrants [Member]
Temporary Equity [Line Items]
Expected life (in years)			5 years
Stock price			$8.91
Exercise price			$12.50
Expected dividend yield			0.00%
Expected volatility			90.00%
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares issued upon conversion of debt		42,245,834
2011 Convertible Bridge Notes [Member]
Temporary Equity [Line Items]
Aggregate amount of loan					5,000,000
Interest rate			8.00%
Conversion price of notes		$0.54	$0.54
Debt instrument initial principal amount							12,336,000
Additional principal payment							0
Debt, principal amount converted		12,336,000
Fair value of warrants reclassified into additional paid-in capital		236,799
Exercise price of warrants		$0.54
Shares of preferred stock converted into shares of common stock	624,705
2011 Convertible Bridge Notes [Member] | Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted		1,832,000
2011 Convertible Bridge Notes [Member] | Warrants [Member]
Temporary Equity [Line Items]
Warrant liability								1,400,000
Expected life (in years)			5 years
Exercise price			$0.54
Expected dividend yield			0.00%
2011 Convertible Bridge Notes [Member] | Warrants [Member] | Minimum [Member]
Temporary Equity [Line Items]
Stock price			$0.25
Average risk free interest rate			0.70%
Expected volatility			100.00%
2011 Convertible Bridge Notes [Member] | Warrants [Member] | Maximum [Member]
Temporary Equity [Line Items]
Stock price			$0.54
Average risk free interest rate			2.26%
Expected volatility			105.00%
2011 Convertible Bridge Notes [Member] | Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Proceeds sale of shares that triggers conversion of debt			20,000,000
Notice period for early termination of warrant			20 days
Shares issued upon conversion of debt		26,237,611
2011 Convertible Bridge Notes [Member] | Preferred Stock
Temporary Equity [Line Items]
Percentage of warrants exercisable			20.00%
2011 Convertible Bridge Notes [Member] | Period One
Temporary Equity [Line Items]
Aggregate amount of loan						6,000,000
2011 Convertible Bridge Notes [Member] | Period Two
Temporary Equity [Line Items]
Aggregate amount of loan						$15,000,000

Convertible_Notes_and_Warrants4

Convertible Notes and Warrants - 2012 Revolver Notes - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 13, 2013	Jan. 13, 2012	Apr. 05, 2012	Nov. 08, 2012
Temporary Equity [Line Items]
Maximum amount of line of credit			$2,600,000
Conversion price of notes	$10		$10
Fair value of the warrants issued			1,070	2,140,532
Debt, principal amount converted	1,400,000	20,231,000	6,600,000	20,231,000
Shares issued upon conversion of debt	163,399
Exercise price of warrants	$10
Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Warrants [Member]
Temporary Equity [Line Items]
Expected life (in years)			5 years
Stock price			$8.91
Exercise price			$12.50
Expected dividend yield			0.00%
Expected volatility			90.00%
Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares issued upon conversion of debt		42,245,834
2012 Revolver Notes [Member]
Temporary Equity [Line Items]
Maximum amount of line of credit							1,750,000
Series of notes, maturity date, month and year			2012-04
Debt Instrument, interest rate payable at maturity							10.00%
Proceeds received from sale of shares that triggers exercise of warrants			20,000,000
Conversion price of notes		$0.54
Notice period for early termination of warrant			20 days
Issuance of notes payable					5,960,000
Principal payments				0
Debt, principal amount converted		5,960,000
Exercise price of warrants						$0.54
Fair value of warrants reclassified into additional paid-in capital						144,000
Shares of preferred stock converted into shares of common stock	291,212
2012 Revolver Notes [Member] | Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted		645,000
2012 Revolver Notes [Member] | Warrants [Member]
Temporary Equity [Line Items]
Fair value of the warrants issued							396,000
Expected life (in years)			5 years
Exercise price			$0.54
Expected dividend yield			0.00%
Expected volatility			105.00%
Accretion of discount recognized as interest expense					396,000
2012 Revolver Notes [Member] | Warrants [Member] | Minimum [Member]
Temporary Equity [Line Items]
Stock price			$0.24
Average risk free interest rate			0.62%
2012 Revolver Notes [Member] | Warrants [Member] | Maximum [Member]
Temporary Equity [Line Items]
Stock price			$0.30
Average risk free interest rate			1.02%
2012 Revolver Notes [Member] | Series A Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Conversion price of notes			$0.54
Shares issued upon conversion of debt		12,230,899
First Amendment [Member] | 2012 Revolver Notes [Member]
Temporary Equity [Line Items]
Maximum amount of line of credit								5,000,000
Extended maturity date, start			31-May-12
Extended maturity date, end			31-Jul-12
Second Amendment [Member] | 2012 Revolver Notes [Member]
Temporary Equity [Line Items]
Maximum amount of line of credit									$8,000,000
Extended maturity date, start			30-Nov-12
Extended maturity date, end			31-Dec-12

Convertible_Notes_and_Warrants5

Convertible Notes and Warrants - Other - Additional Information (Detail) (USD $)	12 Months Ended		0 Months Ended			12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 10, 2014	Sep. 10, 2013	Sep. 10, 2012	Dec. 31, 2012	Sep. 30, 2013
Class Of Warrant Or Right [Line Items]
Warrant coverage amount		$502,605					$502,605
Exercise price of warrants			$10
Preferred warrants outstanding after cancellation of warrants due to early termination clauses			1,587
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings	135,222	309,000
Warrant become exercisable for shares of common stock			50,260
Warrant liability	1,070	2,140,532
Other [Member]
Class Of Warrant Or Right [Line Items]
Warrant coverage amount					40,000
Exercise price of warrants			$10		$0.60
Proceeds received from sale of company preferred shares					15,000,000
Expected life (in years)				5 years	7 years
Notice period for early termination of warrant					20 days
Preferred warrants outstanding after cancellation of warrants due to early termination clauses	1,587	1,587
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings				309,000
Average risk free interest rate				1.38%
Expected dividend yield				0.00%
Expected volatility				105.00%
Fair value assumption, probability rate				25.00%
Fair value price				0
Warrant liability		282,000
Reclassification of common stock warrant liability to APIC upon IPO.			304,000
Other [Member] | Black Scholes Valuation Model
Class Of Warrant Or Right [Line Items]
Fair value assumption, probability rate				75.00%
Other [Member] | Minimum [Member]
Class Of Warrant Or Right [Line Items]
Exercise price				$3.08
Other [Member] | Maximum [Member]
Class Of Warrant Or Right [Line Items]
Exercise price				$14.28
Black Scholes Valuation Model [Member]
Class Of Warrant Or Right [Line Items]
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings						982,000
Stock price						$0.25
Exercise price						$0.54
Expected dividend yield						0.00%
Expected volatility						105.00%
Black Scholes Valuation Model [Member] | Minimum [Member]
Class Of Warrant Or Right [Line Items]
Expected life (in years)						3 years 29 days
Average risk free interest rate						0.35%
Black Scholes Valuation Model [Member] | Maximum [Member]
Class Of Warrant Or Right [Line Items]
Expected life (in years)						4 years 11 months 1 day
Average risk free interest rate						0.70%
Common Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant coverage amount				502,605
Exercise price of warrants			$10
Warrant become exercisable for shares of common stock			50,260
Fair value assumption, probability rate		25.00%
Fair value price		0
Warrant liability		$2,132,000
Common Stock Warrants [Member] | Black Scholes Valuation Model
Class Of Warrant Or Right [Line Items]
Fair value assumption, probability rate		75.00%

Convertible_Notes_and_Warrants6

Convertible Notes and Warrants - 2013 Convertible Bridge Notes - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended		1 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 10, 2014
Temporary Equity [Line Items]
Maximum amount of line of credit			$2,600,000
Exercise price of warrants	$10				$10
Unamortized discounts related to warrants	996,024				996,024
Debt, principal amount converted	1,400,000	20,231,000	6,600,000	20,231,000
Conversion price of notes	$10		$10		$10
Convertible Note converted into preferred/common stock	163,399
Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Major Shareholder [Member] | Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	433,821	2,339,000
2013 Convertible Bridge Notes [Member]
Temporary Equity [Line Items]
Maximum amount of line of credit		7,000,000
Credit facility, net	5,165,000			4,990,000	5,165,000
Interest rate			8.00%
Maturity date			31-May-14
Common stock gross cumulative proceeds				8,000,000
Percentage of warrants exercisable				50.00%
Notice period for early termination of warrant				20 days
Exercise price of warrants				$10
Grant date fair value of liability classified warrants issued				1,612,000
Expected life (in years)				5 years
Expected dividend yield				0.00%
Fair value price				1,399,000
Reclassification of common stock warrant liability to APIC upon IPO.	1,563,000
Accretion of discount recognized as interest expense				685,000	928,000
Unamortized discounts related to warrants			0	874,158
Debt, principal amount converted	5,165,000
Conversion price of notes	$10				$10
Convertible Note converted into preferred/common stock	547,794
2013 Convertible Bridge Notes [Member] | Accrued interest [Member]
Temporary Equity [Line Items]
Accrued interest on convertible debt converted	313,017
2013 Convertible Bridge Notes [Member] | Minimum [Member]
Temporary Equity [Line Items]
Exercise price				$1.48
Average risk free interest rate				1.38%
Expected volatility				100.00%
Fair value assumption, probability percentage				75.00%
Fair value assumption, probability rate				20.00%
2013 Convertible Bridge Notes [Member] | Maximum [Member]
Temporary Equity [Line Items]
Exercise price				$14.28
Average risk free interest rate				1.73%
Expected volatility				105.00%
Fair value assumption, probability percentage				80.00%
Fair value assumption, probability rate				25.00%
2013 Convertible Bridge Notes [Member] | Probability Between Twenty And Twenty Five Percent
Temporary Equity [Line Items]
Fair value price				0
2013 Convertible Bridge Notes [Member] | Major Shareholder [Member]
Temporary Equity [Line Items]
Credit facility, net	$2,505,000			$2,505,000	$2,505,000

Convertible_Notes_and_Warrants7

Convertible Notes and Warrants - Line of Credit - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended			1 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 10, 2014
Line of Credit
Exercise price of warrants	$10					$10
Change in fair value of warrant liability			($200,936)	$782,112	$536,000
Unamortized discounts related to warrants	996,024					996,024
Debt, principal amount converted	1,400,000	20,231,000	6,600,000	20,231,000
Accrued interest [Member]
Line of Credit
Accrued interest on convertible debt converted	233,982	2,581,000		2,581,000
Common Stock Warrants [Member]
Line of Credit
Exercise price of warrants	$10					$10
Fair value assumption, probability rate				25.00%
Fair value price				0
Common Stock Warrants [Member] | Black Scholes Valuation Model
Line of Credit
Fair value assumption, probability rate				75.00%
Common Stock Warrants [Member] | Line of Credit [Member]
Line of Credit
Collateral amount provided to secure Line of Credit	2,578,076					2,578,076
Common stock warrants coverage	50.00%
Exercise price of warrants	$10					$10
Expected life (in years)				2 years
Expected dividend yield				0.00%
Fair value assumption, probability rate				25.00%
Fair value price				0
Fair value of warrants recorded as liability				390,000
Accretion of discount recognized as interest expense				139,000		397,000
Reclassification of common stock warrant liability to APIC upon IPO.	514,000
Unamortized discounts related to warrants				315,000
Debt, principal amount converted	2,346,000
Common Stock Warrants [Member] | Line of Credit [Member] | Accrued interest [Member]
Line of Credit
Accrued interest on convertible debt converted	$27,043
Common Stock Warrants [Member] | Line of Credit [Member] | Black Scholes Valuation Model
Line of Credit
Fair value assumption, probability rate				75.00%
Common Stock Warrants [Member] | Line of Credit [Member] | Minimum [Member]
Line of Credit
Exercise price				$1.48
Average risk free interest rate				0.38%
Expected volatility				90.00%
Common Stock Warrants [Member] | Line of Credit [Member] | Maximum [Member]
Line of Credit
Exercise price				$14.28
Average risk free interest rate				1.38%
Expected volatility				105.00%

Supplier_Financing_Additional_

Supplier Financing - Additional Information (Detail) (Financing Agreements With Supplier [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011
Laboratory equipment [Member]
Debt Instrument [Line Items]
Debt instrument initial principal amount			$177,000
Interest rate			7.40%
Remaining balance under financing agreement		62,000
Laboratory Software [Member]
Debt Instrument [Line Items]
Interest rate	5.95%	5.95%
Remaining balance under financing agreement	34,000	91,000
Financing agreement, due period	1 year
Director [Member]
Debt Instrument [Line Items]
Debt instrument initial principal amount			256,000
Interest rate			0.00%
Financing agreement, average interest rate		8.00%
Interest expense under financing agreement		5,000
Remaining balance under financing agreement		$66,000

Shareholders_Deficit_Additiona

Shareholders' Deficit - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended	12 Months Ended
	Feb. 10, 2014	Jun. 28, 2013	Dec. 31, 2010	Nov. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Feb. 04, 2014	Jul. 31, 2013	Jul. 30, 2013	Jul. 22, 2013	Jul. 21, 2013	Dec. 31, 2012
Class Of Stock [Line Items]
Reverse stock split of common shares, ratio			0.25	0.0714
Common stock, shares authorized					40,000,000	53,000,000	40,000,000			14,600,000
Common stock, par value					$0.00	$0.00		$0.00	$0.00
Preferred stock, shares authorized							5,000,000			100,000,000	14,600,000
Preferred stock, par value						$0.00		$0.00
Preferred stock, dividends, per share, cash paid					8.00%
Initial public offering, price per share							$10
Preferred stock, dividend declared					$0	$0
Preferred stock, voting rights					The holders of preferred shares had the right to one vote for each common share into which the preferred shares were convertible.
Proceeds from sale of common stock					20,000,000
Sales of stock per share					$25.20
Convertible preferred stock, terms of conversion					The convertible preferred shares could have been converted into common shares at any time at the option of the holder utilizing the then effective Series A preferred conversion price. All preferred shares would have been automatically converted into common shares utilizing the then effective Series A preferred conversion price upon a) the election of the holders of a majority of the outstanding shares of Series A preferred stock, or b) the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the sale of the Companybs common stock if gross proceeds are at least $20,000,000 and the per share price is at least $25.20.
Debt, principal amount converted	1,400,000	20,231,000			6,600,000	20,231,000
Accrued interest [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted	$233,982	$2,581,000				$2,581,000
Series A Convertible Preferred Stock [Member]
Class Of Stock [Line Items]
Preferred stock, shares authorized					5,000,000	100,000,000						36,460,000
Preferred stock, par value					$0.00	$0.00			$0.00
Initial public offering, price per share					$0.60
Shares issued for conversion of notes payable and accrued interest, shares						42,245,834
IPO
Class Of Stock [Line Items]
Common stock, shares authorized							40,000,000
Preferred stock, shares authorized							5,000,000

Accounting_for_StockBased_Comp2

Accounting for Stock-Based Compensation Expense - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Feb. 10, 2014

Nov. 30, 2011

Dec. 31, 2010

Nov. 30, 2013

Jul. 31, 2013

Dec. 31, 2013

Mar. 31, 2011

Nov. 30, 2010

Nov. 30, 2011

Dec. 31, 2014

Jun. 12, 2014

Aug. 31, 2013

Feb. 13, 2014

Aug. 14, 2014

Feb. 04, 2014

Jul. 22, 2013

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Reverse stock split of common shares, ratio

0.25

0.0714

Common stock, shares authorized

53,000,000

40,000,000

40,000,000

14,600,000

Option awards vesting period

10 years

Time period for vesting grants in installments on monthly basis

12 months

Proceeds from exercise of stock options

$20,105

Shares of common stock vested as settlement of certain restricted stock units

73,151

Total grants vest period

100.00%

Common stock vesting shares for non employee directors

20,930

20,930

Monthly installments of restricted stock units period

5 months

Underlying award shares will distributed last period year

0

Unrecognized stock-based compensation expense, stock options

2,735,000

Unrecognized stock-based compensation expense, RSU awards

50,000

IPO

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock, shares authorized

40,000,000

Series BB Preferred Stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock unit award, shares

428,597

390,000

Estimated shares of additional restricted stock unit

574,108

Series A Convertible Preferred Stock [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock unit award, shares

574,108

390,000

Stock Options [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Reverse stock split of common shares, ratio

0.25

Option awards vesting period

10 years

Awards vest on date of grant

50.00%

Time period for vesting grants in installments on monthly basis

2 years

Option awards assumptions, method used

Black-Scholes pricing model

Weighted-average estimated fair value of options granted

$4.43

$5.25

Intrinsic value of options exercisable

3,450

Intrinsic value of options outstanding

8,204

0

Proceeds from exercise of stock options

20,105

Intrinsic value of options exercisable

$5,575

$0

Unrecognized stock-based compensation expense, weighted-average recognition period

2 years 7 months 6 days

Stock Options [Member] | Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Option awards vesting period

4 years

Commencement Date of October 2010 [Member] | IPO

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock vested as settlement of certain restricted stock units

9,285

Weighted-average estimated fair value of RSUs vested

4.62

Commencement Date of January 2011 [Member] | IPO

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares of common stock vested as settlement of certain restricted stock units

63,866

Weighted-average estimated fair value of RSUs vested

4.62

RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Awards vest on date of grant

50.00%

Time period for vesting grants in installments on monthly basis

24 months

Weighted-average estimated fair value of options granted

5.6

$5.35

$5.60

Common stock shares granted for three directors

8,735

Common stock shares granted to another director

14,285

RSU awards granted to certain executive employees

60,712

RSU remaining vesting period on equal monthly basis

50.00%

Issuance of restricted stock units

44,496

Unrecognized stock-based compensation expense, weighted-average recognition period

7 months 6 days

2007 Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares reduced during stock reverse split

178,571

Reverse stock split of common shares, ratio

0.0714

Shares available for grant

77,061

86,001

2013 Equity Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Shares available for grant

175,725

Common stock, shares authorized

403,571

Shares increase upon completion of IPO

800,000

Percentage of outstanding common stock

5.00%

Stock options and RSUs granted

1,027,846

Option awards vesting period

3 years

Accounting_for_StockBased_Comp3

Accounting for Stock-Based Compensation Expense - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices		$5.18
Expected dividend yield	0.00%	0.00%
Expected volatility		105.00%
Expected volatility, minimum	90.00%
Expected volatility, maximum	100.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$2.79
Discount rate-bond equivalent yield	1.56%	1.38%
Expected life (in years)	5 years	5 years 3 months 4 days
Expected forfeiture rate	0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$9.11
Discount rate-bond equivalent yield	2.06%	1.69%
Expected life (in years)	6 years 29 days	6 years 7 days
Expected forfeiture rate	5.00%	5.00%

Accounting_for_StockBased_Comp4

Accounting for Stock-Based Compensation Expense - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning Balance	333,106	63,518
Stock options granted	647,298	300,438
Number of Shares, Exercised		-4,021
Number of Shares, Cancelled/forfeited/expired	-74,210	-26,829
Number of Shares Outstanding, Ending Balance	906,194	333,106	63,518
Number of Shares, Vested and unvested expected to vest, Ending Balance	901,882
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$5.14	$4.97
Weighted Average Exercise Price Per Share, Granted	$6.71	$5.18
Weighted Average Exercise Price Per Share, Exercised		$5
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	$4.77	$5.20
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	$6.29	$5.14	$4.97
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$6.28
Average Remaining Contractual Term in Years, Outstanding	9 years	9 years 3 months 18 days	6 years 2 months 12 days
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 10 months 24 days

Accounting_for_StockBased_Comp5

Accounting for Stock-Based Compensation Expense - Schedule of Information about Options Outstanding and Exercisable (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding	333,106	906,194	63,518
Total Shares Exercisable	137,011	325,931
Weighted Average Exercise Price 4.62 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$4.62
Total Shares Outstanding	20,208
Weighted Average Contractual Life (in years)	7 years 3 months 18 days
Total Shares Exercisable	13,731
Weighted Average Exercise Price 5.04 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$5.04	$8.88
Total Shares Outstanding	12,460	238,500
Weighted Average Contractual Life (in years)	5 years 6 months	9 years 1 month 6 days
Total Shares Exercisable	12,455
Weighted Average Exercise Price 5.18 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$125.58
Total Shares Outstanding	300,438
Weighted Average Contractual Life (in years)	9 years 7 months 6 days
Total Shares Exercisable	110,825
Weighted Average Exercise Price 2.79 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price		$2.79
Total Shares Outstanding		52,500
Weighted Average Contractual Life (in years)		9 years 9 months 18 days
Weighted Average Exercise Price 4.42 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price		$4.42
Total Shares Outstanding		103,934
Weighted Average Contractual Life (in years)		8 years 9 months 18 days
Total Shares Exercisable		29,715
Weighted Average Exercise Price 5.22 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price		$5.22
Total Shares Outstanding		413,962
Weighted Average Contractual Life (in years)		8 years 9 months 18 days
Total Shares Exercisable		241,918
Weighted Average Exercise Price 7.50 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price		$7.50
Total Shares Outstanding		43,000
Weighted Average Contractual Life (in years)		9 years 2 months 12 days
Weighted Average Exercise Price 9.11 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price		$9.11
Total Shares Outstanding		54,298
Weighted Average Contractual Life (in years)		9 years 1 month 6 days
Total Shares Exercisable		54,298

Recovered_Sheet1

Accounting for Stock-based Compensation - Schedule of Performance Stock Units Vesting Percentage (Detail) (RSUs [Member])	12 Months Ended
	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	100.00%
Minimum Revenue in 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	25.00%
Maximum EBITDA Loss in 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	15.00%
Attainment of Financial Plan for Fiscal 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	20.00%
Minimum Value of Strategic Agreements by December 31, 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	20.00%
Implementation of Four New Diagnostic Test Panels by December 31, 2015 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of Overall RSU Grant Subject to Vesting	20.00%

Recovered_Sheet2

Accounting for Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$1,399,703	$520,344
Stock Options [Member] | Cost of revenues
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	20,961
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	163,229	298,618
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,139,309	221,726
Stock Options [Member] | Selling and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	76,204
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,822,661	952,521
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	30,000	72,500
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$392,958	$359,677

Net_Loss_per_Common_Share_Addi

Net Loss per Common Share - Additional Information (Detail)	0 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2010	Nov. 30, 2013	Dec. 31, 2014
Earnings Per Share [Abstract]
Reverse stock split of common shares, ratio	0.25	0.0714
Reverse stock split, description			In November 2013, the Company effected a 1:14 reverse stock split of all common shares outstanding. The calculation of weighted-average shares outstanding has been adjusted for this reverse split as if it had occurred on January 1, 2013.

Net_Loss_per_Common_Share_Sche

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,768,586	4,349,376
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		1,652,851
Notes Payable Convertible into Common Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		1,110,649
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,587	192,262
Preferred Share RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	73,151	89,647
Common Warrants Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	609,187	836,890
Common Share RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	178,467	133,971
Common Options Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	906,194	333,106

Income_Tax_Schedule_of_Provisi

Income Tax - Schedule of Provision for Income Taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Current:
State	$1,506	$800
Total	1,506	800
Deferred
Provision for income tax	$1,506	$800

Income_Tax_Reconciliation_of_I

Income Tax - Reconciliation of Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income tax at statutory rate	($5,393,944)	($3,139,368)
State liability	-813,039	-321,058
Permanent items	14,374	6,932
Stock Compensation	159,128	171,003
Nondeductible Interest	399,249	395,089
Expiration of net operating losses	1,136,317	188,316
Other	339,636	-6,723
Research and development credit	-127,491	-103,500
Valuation allowance	4,287,276	2,810,109
Provision for income tax	$1,506	$800

Income_Tax_Additional_Informat

Income Tax - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Contingency [Line Items]
Percent of uncertain income tax positions recognized	50.00%	50.00%
Liability for unrecognized tax benefits	$0	$0
Percentage of change in ownership	50.00%
Period of change in ownership	3 years
Federal [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	124,601,000
Net operating loss carryforwards, expiration year	expiring beginning in 2020
California [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	84,764,000
Net operating loss carryforwards, expiration year	expiring beginning in 2015
Expire in 2015 | California [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	13,655,000
Expire in 2016 | California [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	15,808,000
Expire in 2017 | California [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	55,301,000
Research Tax Credit Carryforward [Member] | Federal [Member]
Income Tax Contingency [Line Items]
Research and development tax credits	3,205,000
Income tax research and development expiration year	begin to expire in 2018
Research Tax Credit Carryforward [Member] | California [Member]
Income Tax Contingency [Line Items]
Research and development tax credits	$3,087,000

Income_Tax_Summary_of_Deferred

Income Tax - Summary of Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$47,329,815	$43,666,636
Research and development credits	5,242,144	5,114,652
Accruals and other	1,216,600	742,045
Deferred rent	198,945	176,893
Gross deferred tax assets	53,987,504	49,700,226
Less valuation allowance	($53,987,504)	($49,700,226)

Collaborative_Agreements_Addit

Collaborative Agreements - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Clarient [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative agreement period of contract	3 years
Revenue earned under collaborative agreement	$8,000	$14,000
Dana Farber Partners Cancer Care, Inc. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue earned under collaborative agreement	43,000	104,000
MD Anderson Cancer Center [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative agreement period of contract	2 years
Revenue earned under collaborative agreement	$3,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

Feb. 10, 2014

Feb. 04, 2014

Jun. 28, 2013

Dec. 31, 2014

Dec. 31, 2013

Feb. 09, 2015

Dec. 31, 2011

Jul. 31, 2013

Jun. 30, 2013

Dec. 31, 2005

Feb. 13, 2015

Jan. 31, 2014

Sep. 30, 2013

Dec. 31, 2008

Dec. 31, 2012

sshs

sshs

Related Party Transaction [Line Items]

Debt, principal amount converted

$1,400,000

$20,231,000

$6,600,000

$20,231,000

Shares issued upon conversion of debt

163,399

Conversion price of notes

$10

$10

Payable to board of director

2,000

2,000

Shares issued for initial public offering, shares

1,900,000

Subsequent Event [Member]

Related Party Transaction [Line Items]

Issuance of warrants to purchase shares of common stock

142,000

1,200,000

Shares issued for initial public offering, shares

142,000

Common stock proceeds

177,500

Line of Credit [Member]

Related Party Transaction [Line Items]

Common stock warrants issued, number of share holders guarantees on companybs borrowings

5

5

5

Major Shareholder [Member]

Related Party Transaction [Line Items]

Debt instrument carrying amount

3,905,000

Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

Debt instrument carrying amount

1,554,000

1,479,000

Shares issued upon conversion of debt

164,104

Conversion price of notes

$10

Number of supplier financing arrangements

2

Board of Directors Chairman [Member] | Financing Agreements With Supplier [Member]

Related Party Transaction [Line Items]

Related party transaction, outstanding

66,000

256,000

Common Stock [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

433,883

163,399

Shares issued for initial public offering, shares

1,900,000

Common Stock [Member] | Major Shareholder [Member]

Related Party Transaction [Line Items]

Conversion price of notes

$10

Accrued interest [Member]

Related Party Transaction [Line Items]

Accrued interest on convertible debt converted

233,982

2,581,000

2,581,000

Accrued interest [Member] | Major Shareholder [Member]

Related Party Transaction [Line Items]

Accrued interest on convertible debt converted

433,821

2,339,000

Accrued interest [Member] | Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

Accrued interest on convertible debt converted

87,531

101,000

2008 Convertible Note [Member]

Related Party Transaction [Line Items]

Debt instrument carrying amount

1,400,000

Debt, principal amount converted

1,400,000

1,400,000

Conversion price of notes

$10

2008 Convertible Note [Member] | Major Shareholder [Member]

Related Party Transaction [Line Items]

Accrued interest on convertible debt converted

3,905,000

17,060,000

2008 Convertible Note [Member] | Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

Debt, principal amount converted

1,554,000

975,000

2008 Convertible Note [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

163,399

Series A Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

42,245,834

Series A Convertible Preferred Stock [Member] | Major Shareholder [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

35,923,845

Series A Convertible Preferred Stock [Member] | Board of Directors Chairman [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

1,993,591

Goodman Note [Member]

Related Party Transaction [Line Items]

Beneficial owner percentage of companybs common stock

5.00%

Debt instrument carrying amount

1,935,000

Debt, principal amount converted

1,935,000

Shares of preferred stock converted into shares of common stock

89,936

Goodman Note [Member] | Accrued interest [Member]

Related Party Transaction [Line Items]

Accrued interest on convertible debt converted

$105,000

Goodman Note [Member] | Series A Convertible Preferred Stock [Member]

Related Party Transaction [Line Items]

Shares issued upon conversion of debt

3,777,324

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	0 Months Ended		5 Months Ended	12 Months Ended
	Feb. 25, 2014	Feb. 10, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Aug. 19, 2013	Nov. 30, 2011
									sqft
Loss Contingencies [Line Items]
Lease expiration date				31-Jul-20
Rent expense				$1,272,000	$1,143,000
Rent in arrears			0	0	0	185,000
Waiver of lease payment			503,000
Forfeiture of long-term deposit			269,000
Period for which warrants will be exercisable beginning with the closing of IPO		5 years
Warrant coverage amount			502,605		502,605		502,605
Warrant become exercisable for shares of common stock		50,260
Exercise price of warrants		$10
Additional cash compensation expense				150,000
Annual cash compensation expense				225,000
Alleged unpaid wages and penalties								65,000
Alleged unpaid wages and penalties, paid	25,000				40,000
Alleged unpaid wages and penalties, accrued			$25,000		$25,000
San Diego California Facility [Member]
Loss Contingencies [Line Items]
Initial lease term						8 years
Lease expiration date				31-Oct-18
Leased facility, expansion of original premises									9,849

Commitments_and_Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
2015	$1,270,501
2016	1,307,187
2017	1,348,257
2018	1,388,705
2019	1,430,366
Thereafter	855,136
Total	$7,600,152

Selected_Quarterly_Financial_D2

Selected Quarterly Financial Data (Unaudited) - Summary of Selected Quarterly Financial Data (Detail) (USD $)	3 Months Ended																12 Months Ended
	Dec. 31, 2014		Sep. 30, 2014		Jun. 30, 2014		Mar. 31, 2014		Dec. 31, 2013		Sep. 30, 2013		Jun. 30, 2013		Mar. 31, 2013		Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Balance sheet data:
Cash & cash equivalents	$5,364,582		$8,819,872		$12,460,565		$10,417,277		$69,178		$302,908		$4,483		$17,964		$5,364,582	$69,178	$185,256
Total assets	6,588,247		9,875,039		13,359,982		11,289,508		1,329,719		1,083,089		991,576		1,095,023		6,588,247	1,329,719
Total non-current liabilities	5,378,033		5,339,618		5,203,742		473,080		462,001		167,291		508,527		1,252,921		5,378,033	462,001
Total shareholdersb equity/(deficit)	-220,569		3,344,897		6,883,269		9,356,778		-12,456,014		-10,272,840		-8,215,261		-29,300,361		-220,569	-12,456,014	-27,384,895
Statement of operations and comprehensive loss data:
Revenues	75,621		10,274		19,245		28,275		18,800		31,922		48,369		35,154		133,415	134,245
Gross profit/(loss)	-539,067		-527,907		-340,119		-630,040		-551,532		-587,158		-544,868		-512,097		-2,037,133	-2,195,655
Research and development expenses	1,070,278		1,310,905		1,107,678		1,008,929		710,845		975,104		690,582		710,206		4,497,790	3,086,737
General and administrative expenses	1,231,418		1,060,812		1,032,855		1,876,912		776,944		806,872		478,163		451,157		5,201,997	2,513,136
Sales and marketing expenses	890,496		812,005		423,361		11,142		19,225		5,342		27,932		96,404		2,137,004	148,903
Loss from operations	-3,731,259		-3,711,629		-2,904,013		-3,527,023		-2,058,546		-2,374,476		-1,741,545		-1,769,864		-13,873,924	-7,944,431
Net loss	($3,881,541)		($3,859,794)		($2,996,840)		($5,127,871)		($2,472,009)		($2,860,191)		($1,975,009)		($1,925,974)		($15,866,046)	($9,233,183)
Net loss per common share:
Basic	($0.87)	[1]	($0.87)	[1]	($0.67)	[1]	($1.96)	[1]	($13.57)	[1]	($15.72)	[1]	($10.83)	[1]	($10.67)	[1]	($3.97)	($50.80)
Diluted	($0.87)	[1]	($0.87)	[1]	($0.67)	[1]	($1.96)	[1]	($13.57)	[1]	($15.72)	[1]	($10.83)	[1]	($10.67)	[1]	($3.97)	($50.80)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	4,449,603		4,449,603		4,449,603		2,617,275		182,203		181,954		182,304		180,540		3,997,797	181,762
Diluted	4,449,603		4,449,603		4,449,603		2,617,275		182,203		181,954		182,304		180,540		3,997,797	181,762
[1]	Basic and diluted net loss per common share are computed independently for each of the components and quarters presented. Therefore, the sum of quarterly basic and diluted per share information may not equal annual basic and diluted net loss per common share.

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	0 Months Ended		12 Months Ended	0 Months Ended
	Feb. 10, 2014	Feb. 04, 2014	Dec. 31, 2014	Feb. 13, 2015	Feb. 09, 2015
Subsequent Event [Line Items]
Shares issued for initial public offering, shares		1,900,000
Exercise price of warrants	$10
Warrants to purchase common stock, period			5 years
Net proceeds from issuance of common stock	$17,400,000		$17,390,240
Shares issued for initial public offering	16,500,000		16,458,104
Additional costs incurred prior to, and associated with IPO, beginning of period	900,000		932,136
Purchase of common stock by underwriters to cover overallotments, number of shares			285,000
Purchase of common stock by underwriters to cover overallotments, per share			$9.30
Overallotment issued to underwriter to purchase common stock, period			45 days
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued for initial public offering, shares					142,000
Issuance of warrants to purchase shares of common stock				1,200,000	142,000
Stock price					$1.25
Common stock proceeds					177,500
Exercise price of warrants				$0.00	$1.56
Warrants to purchase common stock, period					5 years
Net proceeds from issuance of common stock				9,100,000
Shares issued for initial public offering				8,900,000
Additional costs incurred prior to, and associated with IPO, beginning of period				200,000
Purchase of common stock by underwriters to cover overallotments, number of shares				1,200,000
Purchase of common stock by underwriters to cover overallotments, per share				$1.25
Proceeds from warrant exercises				$6,700,000
Overallotment issued to underwriter to purchase common stock, period				45 days
Subsequent Event [Member] | Aegis and Feltl [Member]
Subsequent Event [Line Items]
Shares issued for initial public offering, shares					8,000,000
Issuance of warrants to purchase shares of common stock					8,000,000
Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Shares issued for initial public offering, shares					142,000
Issuance of warrants to purchase shares of common stock					142,000